

Supporting Information

Asymmetric Palladium-Catalyzed Umpolung Cyclization of Allylic Acetate-Aldehyde using Formate as a Reductant

Hirokazu Tsukamoto*, Ayumu Kawase, and Takayuki Doi
*Graduate School of Pharmaceutical Sciences, Tohoku University,
Aramaki-aza aoba 6-3, Aoba-ku, Sendai 980-8578, Japan*

Contents:

General Information	S-1
Experimental Procedures	S-2
References	S-63
NMR spectra	S-64

General Information

Reactions were carried out in clean, dry glassware under argon atmosphere using high quality solvents. Reagents were purchased at the highest commercial quality and used without further purification. Reactions were monitored by thin layer chromatography separations carried out on 0.2 mm E. Merck silica gel plates (60 F254) using UV light as a visualizing agent and phosphomolybdic acid, *p*-anisaldehyde, or potassium permanganate solutions and heat as developing agents. Preparative TLC was performed on 0.75 mm Wakogel[®] B-5F PLC plate. ¹H-NMR spectra (400 and 600 MHz) and ¹³C-NMR spectra (100 and 150 MHz) were recorded on JEOL JNM-AI400 and JEOL JNM-ECA600 spectrometers, respectively. Chemical shifts (δ) are given from TMS (0 ppm) as internal standard for ¹H-NMR and ¹³CDCl₃ (77.0 ppm) for ¹³C-NMR. The following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (double doublet), dt (double triplet), ddd (double double doublet), br.s (broad singlet), br.d (broad doublet). Mass spectra and high resolution mass spectra were measured on JEOL JMS-DX303 and MS-AX500 (for EI) or Thermo Scientific[™] Exactive[™] Plus Orbitrap Mass Spectrometer (for ESI), responsively. IR spectra were recorded on a Shimadzu JASCO FT/IR-4100. Melting points were measured with a Round Science melting point meter RFS-10 and are uncorrected. Analytical HPLC was performed using Daicel Chiralpak AD-H, OD-H or AS-H. Optical rotations ([α]_D) were measured on JASCO P-1010 polarimeter.

Experimental Procedures

Palladium-Catalyzed Umpolung Cyclization of Allylic Acetate-Aldehyde

General procedure for Table 1

To a test tube containing a solution of **13** (1 eq., see Table 1S) in anhydrous MeCN (0.05 M) were added Pd catalyst (10 mol% , Pd(dppe)₂, Pd(PPh₃)₄, Pd₂dba₃-dppe, PdCp(η³-allyl)-dppe, Pd(OAc)₂-dppe, Pd[P(*o*-tolyl)₃]₂-dppe, Pd[P(*o*-tolyl)₃]₂-(*S*)-SEGPHOS (**12a**)) and reductant (3 eq., HCO₂H/Et₃N, HCO₂H/Bu₃N, HSiEt₃, HCO₂H) under argon. The resulting mixture was sealed with a screw cap and stirred at 50 °C (Entries 1, 3-14) or 80 °C (Entry 2) for the time described in Table 1. Then concentrated *in vacuo*. The residue was purified by preparative TLC eluting with 1:1 EtOAc/hexane to afford **11a**.

Table 1S

Entry	Pd cat. (mg, mol%)	Ligand (mg, mol%)	Reductant (μL, mmol)	13 (mg, mmol)	11a (mg, mmol, %, %ee)
1	Pd(dppe) ₂ (45.2, 100)	-	-	13a ; 19.9, 0.050	5.2, 0.015, 31
2	Pd(dppe) ₂ (5.0, 10)	-	-	13a ; 22.3, 0.055	trace
3	Pd(PPh ₃) ₄ (62.7, 100)	-	-	13a ; 21.8, 0.054	trace
4	Pd(dppe) ₂ (3.1, 10)	-	HCO ₂ H/Et ₃ N (3.9/14.4, 0.10)	13a ; 13.8, 0.034	5.3, 0.015, 45
5	Pd(dppe) ₂ (4.2, 10)	-	HCO ₂ H/Bu ₃ N (5.2/32.1, 0.14)	13a ; 18.3, 0.046	7.7, 0.022, 49
6	Pd(dppe) ₂ (4.0, 10)	-	HSiEt ₃ (21.2, 0.13)	13a ; 17.8, 0.044	6.9, 0.020, 45

7	Pd ₂ dba ₃ (2.1, 5)	dppe (1.3, 7.5)	HCO ₂ H/Bu ₃ N (5.1/31.9, 0.14)	13a ; 18.2, 0.045	9.2, 0.027, 59
8	PdCp(η ³ -allyl) (0.9, 10)	dppe (2.6, 15)	HCO ₂ H/Bu ₃ N (4.9/30.5, 0.13)	13a ; 17.4, 0.043	8.9, 0.026, 60
9	Pd(OAc) ₂ (0.8, 10)	dppe (2.1, 15)	HCO ₂ H/Bu ₃ N (4.1/25.2, 0.11)	13a ; 14.4, 0.036	8.5, 0.025 69
10	Pd[P(<i>o</i> -tolyl) ₃] ₂ (2.5, 10)	dppe (2.1, 15)	HCO ₂ H/Bu ₃ N (4.0/24.7, 0.11)	13a ; 14.1, 0.035	9.4, 0.027, 78
11	Pd[P(<i>o</i> -tolyl) ₃] ₂ (3.3, 10)	-	HCO ₂ H/Bu ₃ N (4.0/25.1, 0.11)	13a ; 14.3, 0.036	0, 0, 0
12	Pd[P(<i>o</i> -tolyl) ₃] ₂ (4.2, 10)	(<i>S</i>)-SEGPHOS (5.4, 15)	HCO ₂ H/Bu ₃ N (6.7/44.2, 0.18)	13a ; 23.7, 0.059	17.7, 0.052, 86, 95
13	Pd[P(<i>o</i> -tolyl) ₃] ₂ (2.0, 10)	(<i>S</i>)-SEGPHOS (5.4, 15)	HCO ₂ H (1.1, 0.028)	13b ; 12.2, 0.028	6.8, 0.020, 70, 90
14	Pd[P(<i>o</i> -tolyl) ₃] ₂ (2.2, 10)	(<i>S</i>)-SEGPHOS (2.9, 15)	-	13c ; 12.1, 0.031	5.9, 0.017, 60, 91

General procedure for the Table 2

To a test tube containing a solution of **13** (1 eq., see Table 2S) in anhydrous MeCN (0.05 M) were added Pd[P(*o*-tolyl)₃]₂ (10 mol%), Ligand (15 mol%, (*S*)-SEGPHOS, (*S*)-DM-SEGPHOS), and HCO₂H-Bu₃N (3 eq.) or HCO₂H (1 eq.) under argon. The resulting mixture was sealed with a screw cap and stirred at 50 °C (Entries 1-6, 9-12) or 80 °C (Entries 7, 8) for the time described in Table 2. Then concentrated *in vacuo*. The residue was purified by preparative TLC to afford **11**. The corresponding racemate was also prepared by the same procedure using dppe as a


ligand in place of SEGPHOS.

Table 2S

Entry	13 (mg, mmol)	Pd (mg, mol%)	Ligand (mg, mol%)	Reductant (μ l, mmol)	11 (mg, mmol, %, %ee)
1	(\pm)-13d ; 21.1, 0.061	4.3, 10	(<i>S</i>)-SEGPHOS (5.6, 15)	HCO ₂ H/Bu ₃ N (6.9/45.7, 0.182)	(3<i>S</i>, 4<i>S</i>)-11d ; 8.8, 0.030 50, 90
2	(\pm)-13d ; 15.2, 0.044	3.1, 10	(<i>S</i>)-DM-SEGPHOS (4.7, 15)	HCO ₂ H-Bu ₃ N (4.9/32.8, 0.131)	(3<i>S</i>, 4<i>S</i>)-11d ; 10.3, 0.033 75, 90
3	(\pm)-13e ; 15.6, 0.063	4.5, 10	(<i>S</i>)-DM-SEGPHOS (6.8, 15)	HCO ₂ H-Bu ₃ N (7.1/47.1, 0.188)	(3<i>S</i>, 4<i>S</i>)-11e ; 8.6, 0.045, 72, 97
4	(\pm)-13f ; 11.5, 0.024	1.7, 10	(<i>S</i>)-DM-SEGPHOS (2.6, 15)	HCO ₂ H-Bu ₃ N (2.7/17.7, 0.071)	(1<i>R</i>, 2<i>R</i>)-11f ; 7.1, 0.017 70, 93 (1<i>R</i>, 2<i>S</i>)-11f ; 2.9, 0.007 29, 94
5	(<i>Z</i>)-13f ; 12.7, 0.027	2.0, 10	(<i>S</i>)-DM-SEGPHOS (3.0, 15)	HCO ₂ H-Bu ₃ N (3.1/20.3, 0.082)	(1<i>R</i>, 2<i>R</i>)-11f ; 5.7, 0.013, 49, 97 (1<i>R</i>, 2<i>S</i>)-11f ; 1.3, 0.003, 11, 76

6	(E)-13f ; 16.3, 0.033	2.4, 10	(S)-DM-SEGPHOS (3.6, 15)	HCO ₂ H-Bu ₃ N (3.8/22.9, 0.100)	(1R, 2R)-11f ; 3.3, 0.008 23, 71 (1R, 2S)-11f ; 7.8, 0.018 54, 99
7	(±)-13g ; 24.3, 0.116	8.3, 10	(S)-DM-SEGPHOS (12.5, 15)	HCO ₂ H-Bu ₃ N (13.1/81.4, 0.347)	(1R, 5R)-11g ; 10.1, 0.066 57, 86
8	(±)-13h ; 50.0, 0.223	15.9, 10	(S)-DM-SEGPHOS (24.2, 15)	HCO ₂ H-Bu ₃ N (25.2/157, 0.669)	(1R, 5R)-11h ; 28.6 0.172 77, 91
9	(±)-13i ; 14.1, 0.045	3.2, 10	(S)-DM-SEGPHOS (4.9, 15)	HCO ₂ H (1.7, 0.045)	(3S, 4S)-11i 7.5, 0.028, 62, 69 (3S*, 4R*)-11i ; 1.9, 0.007, 16, 60
10	(±)-13j ; 17.0, 0.052	3.7, 10	(S)-SEGPHOS (4.8, 15)	HCO ₂ H (2.0, 0.052)	(3S, 4S)-11j ; 12.7, 0.045, 86, 76
11	(±)-13k ; 11.0, 0.029	2.1, 10	(S)-DM-SEGPHOS (3.1, 15)	HCO ₂ H (1.1, 0.029)	(3S, 4S)-11k ; 4.9, 0.015, 51, 88
12	13l (E:Z=1:2.5) ; 8.3, 0.023	1.7, 10	(S)-DM-SEGPHOS (2.5, 15)	HCO ₂ H-Bu ₃ N (2.6/16.0, 0.070)	(3S, 4S)-11l ; 4.5, 0.015, 64, 87

(3*S*,4*S*)-1-[(4-Methylphenyl)sulfonyl]-4-(1-phenylethenyl)-3-pyrrolidinol (11a)¹⁾



Yellow oil.

$R_f = 0.53$ (1:4 EtOAc/toluene).

IR ν (neat, cm^{-1}): 3515, 2948, 1339, 1161.

^1H NMR (400 MHz, CDCl_3): δ 7.77 (d, 2H, $J = 7.6$ Hz), 7.35-7.27 (m, 7H), 5.46 (s, 1H), 5.06 (s, 1H), 4.18 (m, 1H), 3.75 (dd, 1H, $J = 8.4, 8.0$ Hz), 3.62 (dd, 1H, $J = 11.4, 3.6$ Hz), 3.42-3.37 (m, 2H), 3.30 (m, 1H), 2.44 (s, 3H), 1.33 (br.s, 1H).

^{13}C NMR (100 MHz, CDCl_3): δ 143.5, 143.2, 140.5, 134.0, 129.7, 128.7, 128.2, 127.5, 126.1, 116.1, 70.4, 55.8, 48.7, 48.5, 21.5.


LRMS (EI) m/z (relative intensity): 343 [$\text{M}]^+$ (42), 299 (11), 279 (15), 226 (10), 188 (100), 130 (25).

HRMS (EI, [$\text{M}]^+$): calcd for $\text{C}_{19}\text{H}_{21}\text{NO}_3\text{S}$, 343.1242; found, 343.1248.


$[\alpha]_D^{24} = +23.1$ (c 1.05 in CHCl_3).

Chiral HPLC: (Daicel Chiralpak AD-H, *i*-propanol/hexane = 20:80, 1.0 mL/min, $\lambda = 254$ nm): $t_R(3R, 4R) = 12.3$ min (minor enantiomer), $t_R(3S, 4S) = 19.9$ min (major enantiomer).

HPLC chromatographs of 11a




Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	12.16	280.482	92.564	50.11
2	19.74	176.853	92.151	49.89



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	12.07	14.071	3.875	2.71
2	19.72	262.730	139.035	97.29

(3*S*, 4*S*)-*tert*-Butyl 3-hydroxy-4-(1-phenylethenyl)pyrrolidine-1-carboxylate (11d)



White solid.

mp = 119-121 °C

IR ν (neat, cm^{-1}): 3423, 2976, 1679, 1418, 1173, 1133, 894, 777, 700.

^1H NMR (400 MHz, CDCl_3) mixture of rotamers: δ 7.37-7.29 (m, 5H), 5.51 (s, 1H), 5.21 (s, 0.5H), 5.20 (s, 0.5H), 4.20 (s, 1H), 3.78 (dd, 0.5H, $J = 8.0, 7.6$ Hz), 3.71 (dd, 0.5H, $J = 10.0, 8.0$ Hz), 3.61-3.51 (m, 3H), 3.38-3.33 (m, 1H), 1.66 (s, 1H), 1.47 (s, 9H).

^{13}C NMR (100 MHz, CDCl_3) mixture of rotamers: δ 154.6, 144.0, 143.9, 141.0, 128.6, 128.0, 126.2, 116.2, 115.8, 79.4, 70.7, 69.9, 54.1, 53.8, 48.7, 48.0, 46.7, 46.2, 28.5.

LRMS (EI) m/z (relative intensity): 289 [M^+] (4), 233 (100), 215 (19).


HRMS (EI, [M^+]): calcd for $\text{C}_{17}\text{H}_{23}\text{NO}_3$, 289.1678; found, 289.1672.

$[\alpha]_D^{24} = +30.8$ (c 1.01 in CHCl_3).

Chiral HPLC: (Daicel Chiralpak AD-H, *i*-propanol/hexane =20:80, 0.5 mL/min, $\lambda = 254$ nm):


$t_R(3R, 4R) = 9.4$ min (minor enantiomer), $t_R(3S, 4S) = 12.1$ min (major enantiomer).

The relative stereochemistry was determined by NOESY correlation as shown below.




NOESY correlation of **11d**

HPLC chromatographs of **11d**




Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	9.54	130.26	26.634	50.33
2	12.18	104.011	26.282	49.67



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	9.44	18.894	4.134	5.29
2	12.01	290.960	73.971	94.71

Determination of the absolute configurations of **11d**


11d was converted into both (*R*)- and (*S*)-MTPA esters ((*R*)- or (*S*)-Mosher's acid, DCC, DMAP, CH₂Cl₂) and then the absolute configurations were determined by Mosher's ester analysis as (3*S*, 4*S*).²⁾



(*R*)-MTPA-(3*S*,4*S*)-**11d**: ^1H NMR (600 MHz, CDCl_3): mixture of rotamers δ 7.43-7.35 (m, 10H), 5.40 (5.37) (m, 1H), 5.38 (5.33) (s, 1H), 5.07 (5.05) (s, 1H), 3.85 (3.80) (m, 1H), 3.72-3.65 (m, 1H), 3.60-3.46 (m, 3H), 3.40 (3.42) (s, 3H), 1.47 (1.44) (s, 9H).

(*S*)-MTPA-(3*S*,4*S*)-**11d**: ^1H NMR (600 MHz, CDCl_3): mixture of rotamers δ 7.43-7.35 (m, 10H), 5.36 (5.32) (m, 1H), 5.20 (5.19) (s, 1H), 4.99 (4.97) (s, 1H), 3.90 (3.81) (dd, 1H, $J = 9.6$, 7.8 Hz), 3.74-3.57 (m, 3H), 3.50 (m, 1H), 3.44 (s, 3H), 1.50 (1.47) (s, 9H).

(3*S*, 4*S*)-4-(1-Phenylethenyl)oxolan-3-ol (**11e**)



Yellow oil

IR ν (neat, cm^{-1}): 3421, 2926, 1071, 906, 777, 701.

^1H NMR (400 MHz, CDCl_3): δ 7.43-7.26 (m, 5H), 5.54 (s, 1H), 5.13 (s, 1H), 4.31 (m, 1H), 4.13 (dd, 2H, $J = 8.0$, 8.0 Hz), 4.08 (dd, 1H, $J = 10.0$, 4.0 Hz), 3.99 (dd, 1H, $J = 10.4$, 8.0 Hz), 3.89 (dd, 1H, $J = 10.0$, 1.2 Hz), 3.39 (m, 1H), 1.68 (d, 1H, $J = 2.8$ Hz).

^{13}C NMR (100 MHz, CDCl_3): δ 143.3, 141.4, 128.6, 128.0, 126.1, 115.9, 75.8, 71.5, 69.2, 49.8.

LRMS (EI) m/z (relative intensity): 190 [M] $^+$ (3), 172 (5), 159 (13), 131 (100).


HRMS (EI, [M] $^+$): calcd for $\text{C}_{12}\text{H}_{14}\text{O}_2$, 190.0994; found, 190.0979.

$[\alpha]_D^{24} = +6.76$ (c 0.80 in CHCl_3).

Chiral HPLC: (Daicel Chiralpak OD-H, *i*-propanol/hexane = 1:10, 1.0 mL/min, $\lambda = 254$ nm):


$t_R(3R, 4R) = 19.3$ min (minor enantiomer), $t_R(3S, 4S) = 24.9$ min (major enantiomer).

The relative stereochemistry was determined by NOESY correlation as shown below.




NOESY correlation of **11e**

HPLC chromatographs of **11e**




Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	19.27	105.214	42.328	51.40
2	24.75	78.592	40.026	48.60



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	21.03	6.521	1.475	1.59
2	26.16	178.224	91.135	98.41

Determination of the absolute configurations of **11e**


11e was converted into both (*R*)- and (*S*)-MTPA esters ((*R*)- or (*S*)-Mosher's acid, DCC, DMAP, CH₂Cl₂) and then the absolute configurations were determined by Mosher's ester analysis as (3*S*, 4*S*).²⁾



(R)-MTPA-(3*S*,4*S*)-11e: $^1\text{H NMR}$ (600 MHz, CDCl_3): δ 7.39-7.38 (m, 1H), 7.34-7.31 (m, 9H), 5.47 (dd, 1H, $J = 4.2, 4.2$ Hz), 5.38 (s, 1H), 4.97 (s, 1H), 4.32 (dd, 1H, $J = 11.4, 4.2$ Hz), 4.24 (dd, 1H, $J = 7.8, 7.8$ Hz), 3.99 (dd, 1H, $J = 11.4, 7.8$ Hz), 3.89 (d, 1H, $J = 11.4$ Hz), 3.56-3.52 (m, 1H), 3.41 (s, 3H).

(S)-MTPA-(3*S*,4*S*)-11e: $^1\text{H NMR}$ (600 MHz, CDCl_3): δ 7.39 (m, 3H), 7.36-7.32 (m, 2H), 7.26 (m, 3H), 7.19-7.17 (m, 2H), 5.45 (dd, 1H, $J = 4.2, 4.2$ Hz), 5.22 (d, 1H, $J = 1.2$ Hz), 4.91 (d, 1H, $J = 1.2$ Hz), 4.28-4.26 (m, 2H), 4.05 (dd, 1H, $J = 11.4, 7.8$ Hz), 3.98 (d, 1H, $J = 11.4$ Hz), 3.54 (m, 1H), 3.45 (s, 3H).

(1*R*, 2*R*)-4,4-Bis[(benzyloxy)methyl]-2-(1-phenylethenyl)cyclopentan-1-ol (11f)



Yellow oil

IR ν (neat, cm^{-1}): 3467, 3029, 2856, 1454, 1094, 735, 698.

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.36-7.22 (m, 15H), 5.35 (s, 1H), 5.15 (s, 1H), 4.61 (d, 1H, $J = 10.8$ Hz), 4.54 (d, 1H, $J = 10.8$ Hz), 4.51 (s, 2H), 4.01 (m, 1H), 3.47 (s, 2H), 3.36 (s, 2H), 3.08 (m, 1H), 2.69 (d, 1H, $J = 7.2$ Hz), 2.02 (dd, 1H, $J = 7.2, 6.0$ Hz), 1.86-1.75 (m, 3H).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 147.7, 142.6, 138.5, 138.0, 128.4, 128.3, 128.2, 127.7, 127.6, 127.5, 127.4, 127.2, 126.4, 114.1, 75.8, 75.6, 73.5, 73.3, 73.3, 50.1, 45.7, 41.5, 33.0.


LRMS (EI) m/z (relative intensity): 428 [M^+] (5), 410 (3), 320 (25), 319 (43).

HRMS (EI, [M^+]): calcd for $\text{C}_{29}\text{H}_{32}\text{O}_3$, 428.2351; found, 428.2341.

$[\alpha]_D^{26} = +22.0$ (c 0.98 in CHCl_3).


Chiral HPLC: (Daicel Chiralpak OD-H, *i*-propanol/hexane = 1:10, 0.5 mL/min, $\lambda = 254$ nm): $t_R(1S, 2S) = 11.6$ min (minor enantiomer), $t_R(1R, 2R) = 50.7$ min (major enantiomer).

The relative stereochemistry was determined by NOESY correlation as shown below.




NOESY correlation of **11f**

HPLC chromatographs of **11f**




Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	17.24	415.054	302.559	49.70
2	20.85	362.402	306.171	50.30



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	17.57	81.085	44.322	3.55
2	20.08	909.609	1203.237	96.45

Determination of the absolute configurations of **11f**


11f was converted into both (*R*)- and (*S*)-MTPA esters ((*R*)- or (*S*)-Mosher's acid, DCC, DMAP, CH₂Cl₂) and then the absolute configurations were determined by Mosher's ester analysis as (1*R*, 2*R*).²⁾



(*R*)-MTPA-(1*R*, 2*R*)-**11f**: $^1\text{H NMR}$ (600 M Hz, CDCl_3): δ 7.42-7.24 (m, 20H), 5.36 (dd, 1H, $J = 4.8, 4.8$ Hz), 5.30 (s, 1H), 5.09 (s, 1H), 4.53 (s, 2H), 4.31 (s, 2H), 3.46 (s, 2H), 3.44 (s, 3H), 3.41 (m, 1H), 3.16 (d, 1H, $J = 9.0$ Hz), 3.14 (d, 1H, $J = 9.0$ Hz), 2.05 (dd, 1H, $J = 15.6, 4.8$ Hz), 1.98 (dd, 1H, $J = 13.2, 6.6$ Hz), 1.86 (dd, 1H, $J = 13.2, 13.2$ Hz), 1.75 (d, 1H, $J = 15.6$ Hz).

(*S*)-MTPA-(1*R*, 2*R*)-**11f**: $^1\text{H NMR}$ (600 M Hz, CDCl_3): δ 7.43-7.25 (m, 18H), 7.19-7.17 (m, 2H), 5.39 (dd, 1H, $J = 4.2, 4.2$ Hz), 5.17 (s, 1H), 5.00 (s, 1H), 4.54 (s, 2H), 4.46 (d, 1H, $J = 12.0$ Hz), 4.43 (d, 1H, $J = 12.0$ Hz), 3.48 (s, 2H), 3.39 (m, 1H), 3.33 (m, 5H), 2.05 (dd, 1H, $J = 15.6, 4.8$ Hz), 2.01 (dd, 1H, $J = 13.2, 6.6$ Hz), 1.87 (dd, 1H, $J = 13.2, 13.2$ Hz), 1.86 (d, 1H, $J = 15.6$ Hz).

(1*R*, 2*S*)-4,4-Bis[(benzyloxy)methyl]-2-(1-phenylethenyl)cyclopentan-1-ol (**11f'**)



Yellow oil.

IR ν (neat, cm^{-1}): 3417, 3029, 2855, 1495, 1453, 1363, 1095, 735, 698.

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.35-7.25 (m, 15H), 5.21 (s, 1H), 5.10 (s, 1H), 4.54 (s, 2H), 4.46 (s, 2H), 4.18 (m, 1H), 3.44 (d, 1H, $J = 8.8$ Hz), 3.41 (d, 1H, $J = 8.8$ Hz), 3.30 (d, 1H, $J = 8.8$ Hz), 3.27 (d, 1H, $J = 8.8$ Hz), 3.02 (m, 1H), 2.34 (brs, 1H), 2.08 (dd, 1H, $J = 13.6, 7.2$ Hz), 2.00 (dd, 1H, $J = 13.6, 8.0$ Hz), 1.63 (dd, 1H, $J = 13.6, 7.2$ Hz), 2.00 (dd, 1H, $J = 13.6, 9.6$ Hz).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 150.4, 142.2, 138.6, 138.3, 128.4, 128.3, 128.2, 127.6, 127.5, 127.4, 127.4, 127.3, 126.7, 111.6, 76.2, 75.8, 75.6, 73.4, 73.2, 51.9, 44.4, 40.7, 36.2.

LRMS (EI) m/z (relative intensity): 428 [$\text{M}]^+$ (4), 410 (3), 337 (29), 319 (51), 302 (28).


HRMS (EI, [$\text{M}]^+$): calcd for $\text{C}_{29}\text{H}_{32}\text{O}_3$, 428.2351; found, 428.2336.

$[\alpha]_D^{26} = -18.7$ (c 0.96 in CHCl_3).

Chiral HPLC: (Daicel Chiralpak OD-H, *i*-propanol/hexane = 1:10, 0.5 mL/min, $\lambda = 254$ nm):


$t_R(1R, 2S) = 18.8$ min (major enantiomer), $t_R(1S, 2R) = 43.7$ min (minor enantiomer).

The relative stereochemistry was determined by NOESY correlation as shown below.




NOESY correlation of **11f**

HPLC chromatographs of **11f**




Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	19.60	212.165	127.568	49.24
2	45.89	65.493	131.520	50.76



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	20.72	336.382	243.303	97.20
2	50.58	2.576	6.996	2.80

Determination of the absolute configurations of **11f**


11f was converted into both (*R*)- and (*S*)-MTPA esters ((*R*)- or (*S*)-Mosher's acid, DCC, DMAP, CH₂Cl₂) and then the absolute configurations were determined by Mosher's ester analysis as (1*R*, 2*S*).²⁾



(*R*)-MTPA-(3*S*,4*S*)-**11f'**: $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.48-7.46 (m, 2H), 7.37-7.23 (m, 18H), 5.51 (m, 1H), 5.27 (s, 1H), 5.17 (s, 1H), 4.50 (s, 2H), 4.44 (s, 2H), 3.46 (s, 3H), 3.36-3.27 (m, 5H), 2.32 (dd, 1H, $J = 13.6, 7.6$ Hz), 2.00 (dd, 1H, $J = 13.2, 8.0$ Hz), 1.58-1.53 (m, 1H), 1.46 (dd, 1H, $J = 13.2, 12.0$ Hz).

(*S*)-MTPA-(3*S*,4*S*)-**11f'**: $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.48-7.47 (m, 2H), 7.34-7.20 (m, 18H), 5.51 (m, 1H), 5.16 (s, 1H), 5.08 (s, 1H), 4.49 (s, 2H), 4.48 (s, 2H), 3.46 (s, 3H), 3.39 (d, 1H, $J = 8.8$ Hz), 3.36 (d, 1H, $J = 8.8$ Hz), 3.35 (d, 1H, $J = 8.8$ Hz), 3.31 (d, 1H, $J = 8.8$ Hz), 3.27-3.20 (m, 1H), 2.33 (dd, 1H, $J = 13.6, 7.6$ Hz), 1.97 (dd, 1H, $J = 13.6, 8.4$ Hz), 1.72 (dd, 1H, $J = 13.6, 7.6$ Hz), 1.44 (dd, 1H, $J = 13.6, 11.6$ Hz).

(1*R*,5*R*)-6-Methylenespiro[4.4]nonan-1-ol (**11g**)



Colorless oil.

IR ν (neat, cm^{-1}): 3449, 2959, 2868, 1730, 1448, 1404, 1261, 1162, 1069, 802.


$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 5.14 (s, 1H), 4.93 (s, 1H), 3.55 (d, 1H, $J = 4.8$ Hz), 2.45-2.40 (m, 1H), 2.01-1.73 (m, 5H), 1.67-1.44 (m, 6H).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 155.6, 107.4, 76.8, 58.9, 38.8, 35.7, 34.1, 32.6, 22.7, 21.4.

MS: structurally significant fragment peaks were not observed in EI, ESI and FAB mass spectrum.


$[\alpha]_{\text{D}}^{20} = -37.7$ (c 0.55 in CHCl_3).

The relative stereochemistry was determined by NOESY correlation as shown below.



NOESY correlation of **11g**

Determination of the enantiomeric excess of **11g**



11g was converted into its *p*-nitrobenzoyl ester (*p*-NO₂BzCl, Et₃N, DMAP, DCM) and then enantiomeric excess was determined by chiral HPLC.

IR ν (neat, cm⁻¹): 2956, 1722, 1527, 1276, 718.

¹H NMR (400 MHz, CDCl₃): δ 8.28-8.26 (m, 2H), 8.16-8.14 (m, 2H), 5.14 (m, 1H), 4.86 (s, 1H), 4.79 (s, 1H), 2.49-2.43 (m, 1H), 2.38-2.26 (m, 2H), 2.12-2.05 (m, 1H), 1.97-1.89 (m, 2H), 1.81-1.57 (m, 6H).


¹³C NMR (100 MHz, CDCl₃): δ 174.5, 163.9, 153.9, 136.6, 130.5, 123.5, 107.5, 82.0, 57.6, 39.2, 36.8, 33.8, 31.5, 22.6, 21.7.

LRMS (EI) *m/z* (relative intensity): 301 [M]⁺ (0.2), 283 (1.6), 257 (4.2), 150 (18), 134 (100).


HRMS (EI, [M]⁺): calcd for C₁₇H₁₉NO₄, 301.1314; found, 301.1344.

Chiral HPLC: (Daicel Chiralpak OD-H, *i*-propanol/hexane =1:100, 0.5 mL/min, λ = 254 nm): *t*_R(1*S*, 5*S*) = 15.2 min (minor enantiomer), *t*_R(1*R*, 5*R*) = 16.0 min (major enantiomer).

HPLC chromatographs of *p*-nitrobenzoyl ester of **11g**




Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	14.97	833.461	255.050	49.32
2	15.80	776.156	262.055	50.68



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	15.21	63.807	17.997	6.95
2	16.00	746.775	241.106	93.05

Determination of the absolute configurations of **11g**



To the solution of **11g** (7.9 mg, 0.051 mmol) in THF/H₂O/^tBuOH (1/1/1, 1 mL) was added solution of OsO₄ (0.05 M in THF, 51.9 μL, 0.003 mmol). The mixture was stirred at room temperature for 30 min before addition of NaIO₄ (27.7 mg, 0.130 mmol). The mixture was stirred at room temperature for 6 h, and then treated with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with aqueous Na₂S₂O₃ and brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (14:1)] to afford (5*R*, 6*R*)-6-hydroxyspiro[4.4]nonan-1-one³ (5.8 mg, 73%) as a colorless oil.

R_f = 0.19 (4:1 hexane/EtOAc).

IR ν (neat, cm⁻¹): 3445, 2957, 2869, 1732.

¹H NMR (400 MHz, CDCl₃): δ 4.01 (br s, 1H), 3.42 (br s, 1H), 2.34-2.30 (m, 2H), 2.02-1.56 (m, 10H).


¹³C NMR (100 MHz, CDCl₃): δ 225.4, 80.4, 58.8, 39.1, 35.6, 34.4, 33.9, 21.3, 19.3.

LRMS (EI) m/z (relative intensity): 154 [M]⁺ (24), 136 (50), 110 (56), 97 (100).

HRMS (EI, [M]⁺): calcd for C₉H₁₄O₂, 154.0994; found, 154.0991.

[α]_D²⁶ = +34.6 (*c* 1.05 in CHCl₃). (lit. ³) [α]_D²⁶ = +47.7 (*c* 2.00 in CHCl₃)

(1*R*, 5*R*)-6-Methylenespiro[4.5]decan-1-ol (11h)



Colorless oil.

IR ν (neat, cm^{-1}): 3453, 2932, 2857, 1639, 1445, 1040, 876.


^1H NMR (400 MHz, CDCl_3): δ 4.97 (s, 1H), 4.84 (s, 1H), 4.19 (m, 1H), 2.35-2.30 (m, 1H), 2.18-2.08 (m, 2H), 2.04-1.95 (m, 1H), 1.87-1.74 (m, 3H), 1.69-1.49 (m, 4H), 1.41-1.33 (m, 2H), 1.29-1.16 (m, 2H).

^{13}C NMR (100 MHz, CDCl_3): δ 150.7, 110.5, 74.2, 54.8, 35.9, 34.9, 32.8, 31.6, 28.3, 22.6, 20.0.

HRMS (EI, $[\text{M}]^+$): calcd for $\text{C}_{11}\text{H}_{18}\text{O}$, 166.1358; found, 166.1342.


$[\alpha]_{\text{D}}^{21} = -20.0$ (c 0.38 in CHCl_3).

The relative stereochemistry was determined by NOESY correlation as shown below.



NOESY correlation of **11h**

Determination of the enantiomeric excess of 11h



11h was converted into its *p*-nitrobenzoyl ester (*p*- NO_2BzCl , Et_3N , DMAP, DCM) and then enantiomeric excess was determined by chiral HPLC.

IR ν (neat, cm^{-1}): 2934, 2858, 1721, 1527, 1347, 1279, 1120, 719.

^1H NMR (400 MHz, CDCl_3): δ 8.26-8.24 (m, 2H), 8.14-8.11 (m, 2H), 5.57 (m, 1H), 4.81 (m, 2H), 2.34-2.28 (m, 2H), 2.25-2.20 (m, 1H), 2.02 (dt, 1H, $J = 13.2, 4.4$ Hz), 1.89-1.75 (m, 5H), 1.69-1.56 (m, 2H), 1.49-1.47 (m, 1H), 1.38-1.29 (m, 1H), 1.25-1.21 (m, 1H).

^{13}C NMR (100 MHz, CDCl_3): δ 164.2, 151.1, 150.4, 136.3, 130.6, 123.4, 107.9, 79.8, 53.3, 36.2, 34.9, 34.2, 31.0, 28.6, 22.7, 20.2.


LRMS (EI) m/z (relative intensity): 315 $[\text{M}]^+$ (0.5), 297 (8.7), 271 (2.5), 148 (100).

HRMS (EI, $[\text{M}]^+$): calcd for $\text{C}_{18}\text{H}_{21}\text{NO}_4$, 315.1471; found, 315.1463.


Chiral HPLC: (Daicel Chiralpak AD-H, *i*-propanol/hexane = 1:500, 0.5 mL/min, $\lambda = 254$ nm):

$t_{\text{R}}(1*S*, 5*S*) = 32.6$ min (minor enantiomer), $t_{\text{R}}(1*R*, 5*R*) = 35.9$ min (major enantiomer).

HPLC chromatographs of *p*-nitrobenzoyl ester of **11h**




Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	32.07	163.513	213.920	50.98
2	35.95	193.856	205.711	49.02



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	32.58	43.427	24.452	4.74
2	35.95	264.205	491.254	95.26

Determination of the absolute configurations of **11h**



To a solution of **11h** (33.4 mg, 0.201 mmol) in anhydrous DCM (1 mL) was added DMP (170 mg, 0.402 mmol). The mixture was stirred at room temperature for 3 h, and then treated with aqueous Na₂S₂O₃ and aqueous NaHCO₃. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with aqueous Na₂S₂O₃ and brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was dissolved in THF/H₂O/^tBuOH (1/1/1, 5 mL), and treated with a solution of OsO₄ (0.05 M in THF, 201 μL, 0.010 mmol). The mixture was

stirred at room temperature for 30 min before addition of NaIO₄ (107 mg, 0.502 mmol). The mixture was stirred at room temperature for 6 h, and then treated with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with aqueous Na₂S₂O₃ and brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (14:1)] to afford (*R*)-spiro[4.5]decane-1,6-dione³⁾ (20.1 mg, 60%) as a colorless oil.

R_f = 0.43 (4:1 hexane/EtOAc).

IR ν (neat, cm⁻¹): 2944, 2864, 1747, 173, 1698, 1447.

¹H NMR (400 MHz, CDCl₃): δ 2.73-2.64 (m, 2H), 2.44 (dt, 1H, *J* = 14.4, 5.2 Hz), 2.33-2.29 (m, 2H), 2.17-2.10 (m, 1H), 2.09-1.99 (m, 2H), 1.97-1.85 (m, 2H), 1.80-1.55 (m, 4H).


¹³C NMR (100 MHz, CDCl₃): δ 215.7, 208.1, 64.4, 39.8, 38.5, 35.9, 33.7, 26.7, 21.0, 19.0.

LRMS (EI) *m/z* (relative intensity): 166 [M]⁺ (69), 148 (21), 138 (64), 121 (23), 111 (100).

HRMS (EI, [M]⁺): calcd for C₁₀H₁₄O₂, 166.0994; found, 166.0973.

[α]_D²⁶ = +132 (*c* 0.575 in CHCl₃). (lit.³⁾ [α]_D²⁶ = +185 (*c* 0.40 in CHCl₃)

(3*S*, 4*S*)-1-[(4-Methylphenyl)sulfonyl]-4-vinyl-3-pyrrolidinol (11i)⁴⁾



Yellow oil.

IR ν (neat, cm⁻¹): 3508, 2925, 1725, 1598, 1340, 1162, 1092, 1056, 815, 757, 669.

¹H NMR (400 MHz, CDCl₃): δ 7.72 (d, 2H, *J* = 8.4 Hz), 7.31 (d, 2H, *J* = 8.4 Hz), 5.74 (ddd, 1H, *J* = 17.6, 10.4, 7.2), 5.23 (d, 1H, *J* = 10.4 Hz), 5.14 (d, 1H, *J* = 17.6 Hz), 4.20 (m, 1H), 3.58-3.50 (m, 2H), 3.34 (dd, 1H, *J* = 11.4, 1.6 Hz), 3.21 (dd, 1H, *J* = 10.0, 10.0 Hz), 2.75-2.68 (m, 1H), 2.42 (s, 3H), 1.46 (brs, 1H).

¹³C NMR (100 MHz, CDCl₃): δ 143.5, 134.0, 132.4, 129.7, 127.5, 119.5, 72.5, 55.7, 49.1, 47.8, 21.5.

LRMS (EI) *m/z* (relative intensity): 267 [M]⁺ (76), 184 (72), 155 (42), 112 (100).


HRMS (EI, [M]⁺): calcd for C₁₃H₁₇NO₃S, 267.0929; found, 267.0919.

[α]_D²⁴ = +4.46 (*c* 0.50 in CHCl₃).

Chiral HPLC: (Daicel Chiralpak AD-H, *i*-propanol/hexane =10:90, 1.0 mL/min, λ = 254 nm):

*t*_R(3*S*, 4*S*) = 24.4 min (major enantiomer), *t*_R(3*R*, 4*R*) = 47.1 min (minor enantiomer).

(3*S, 4*R**)-1-[(4-Methylphenyl)sulfonyl]-4-vinyl-3-pyrrolidinol (**11i'**)⁵⁾**



Yellow oil.

¹H NMR (400 MHz, CDCl₃): δ 7.72 (d, 2H, *J* = 8.4 Hz), 7.33 (d, 2H, *J* = 8.4 Hz), 5.55 (ddd, 1H, *J* = 18.4, 10.8, 8.0), 5.12 (m, 1H), 5.08 (m, 1H), 3.99 (m, 1H), 3.59-3.53 (m, 2H), 3.18-3.12 (m, 1H), 2.59(m, 1H), 2.42 (s, 3H), 1.70 (m, 1H).


¹³C NMR (100 MHz, CDCl₃): δ 135.3, 129.7, 127.9, 127.5, 121.8, 117.9, 74.8, 53.7, 50.6, 50.4, 21.5.

[α]_D²⁵ = -13.3 (*c* 0.14 in CHCl₃).


Chiral HPLC: (Daicel Chiralpak AD-H, *i*-propanol/hexane =10:90, 1.0 mL/min, λ = 254 nm): *t*_R(3*S*, 4*R*) = 23.9 min (major enantiomer), *t*_R(3*R*, 4*S*) = 25.4 min (minor enantiomer).

The absolute configurations of major enantiomer of **11i'** have not yet been assigned.


HPLC chromatographs of **11i** and **11i'**



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	21.76	5.652	3.505	43.43
2	22.56	0.943	0.525	6.51
3	23.45	0.881	0.543	6.72
4	41.07	2.795	3.498	43.34




Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	21.50	428.445	261.429	81.85
2	41.23	55.446	57.984	18.15



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	23.86	101.018	68.628	80.12
2	25.42	26.056	17.031	19.88

(3*S*, 4*S*)-4-(Prop-1-en-2-yl)-1-tosylpyrrolidin-3-ol (11j)



Yellow oil

IR ν (neat, cm^{-1}): 3509, 2920, 1339, 1161, 1091, 671, 605.

^1H NMR (400 MHz, CDCl_3): δ 7.73 (d, 2H, $J = 8.4$ Hz), 7.31 (d, 2H, $J = 8.4$ Hz), 5.03 (s, 1H), 4.73 (s, 1H), 4.28-4.26 (m, 1H), 3.58-3.51 (m, 2H), 3.44 (d, 1H, $J = 11.6$ Hz), 3.31 (dd, 1H, $J = 11.6, 9.2$ Hz), 2.66-2.61 (m, 1H), 2.43 (s, 3H), 1.77 (s, 3H), 1.42 (brs, 1H).

^{13}C NMR (100 MHz, CDCl_3): δ 143.4, 139.5, 134.0, 129.6, 127.5, 113.9, 70.2, 55.9, 50.5, 47.7,

22.9, 21.5.


HRMS (ESI, $[M+Na]^+$): calcd for $C_{14}H_{19}NO_3SNa$, 304.0983; found, 304.0972.

$[\alpha]_D^{26} = +4.58$ ($c = 1.00$ in $CHCl_3$).


Chiral HPLC: (Daicel Chiralpak AD-H, *i*-propanol/hexane =20:80, 1.0 mL/min, $\lambda = 254$ nm):

$t_R(3S, 4S) = 9.7$ min (major enantiomer), $t_R(3R, 4R) = 13.1$ min (minor enantiomer).

HPLC chromatographs of **11j**




Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	6.43	69.106	16.990	50.81
2	10.58	47.232	16.448	49.19



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	6.39	445.930	92.832	87.97
2	9.28	47.076	12.692	12.03

(3*S*, 4*S*)-1-Tosyl-4-{1-(trimethylsilyl)vinyl}pyrrolidin-3-ol (11k)



Brown solid

Mp = 113-4 °C.

IR ν (neat, cm^{-1}): 3523, 2954, 1340, 1250, 1161, 839, 668.

^1H NMR (400 MHz, CDCl_3): δ 7.74 (d, 2H, $J = 8.4$ Hz), 7.32 (d, 2H, $J = 8.4$ Hz), 5.65 (m, 2H), 4.12 (m, 1H), 3.60 (ddd, 1H, $J = 12.0, 4.4, 1.2$ Hz), 3.50 (dd, 1H, $J = 9.2, 6.8$ Hz), 3.42 (d, 1H, $J = 11.6$ Hz), 3.34 (dd, 1H, $J = 11.6, 9.2$ Hz), 2.87 (m, 1H), 2.43 (m, 4H), 0.11 (s, 9H).


^{13}C NMR (100 MHz, CDCl_3): δ 146.3, 143.4, 14.1, 129.6, 128.2, 127.5, 70.5, 55.9, 48.5, 48.1, 21.5, -1.62.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{16}\text{H}_{25}\text{NO}_3\text{SSiNa}$, 362.1222; found, 362.1211.


$[\alpha]_{\text{D}}^{29} = -11.2$ ($c = 0.10$ in CHCl_3).

Chiral HPLC: (Daicel Chiralpak AD-H, *i*-propanol/hexane = 10:90, 0.5 mL/min, $\lambda = 254$ nm): $t_{\text{R}}(3R, 4R) = 20.4$ min (minor enantiomer), $t_{\text{R}}(3S, 4S) = 21.7$ min (major enantiomer).

HPLC chromatographs of 11k




Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	20.20	520.842	221.367	49.96
2	21.70	502.952	221.692	50.04



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	20.41	11.997	4.664	5.79
2	21.71	179.048	75.941	94.21

(3*S*, 4*S*)-4-(1-Chlorovinyl)-1-tosylpyrrolidin-3-ol (11l)



Yellow oil

IR ν (neat, cm^{-1}): 3507, 2928, 1340, 1161, 669, 605.

^1H NMR (400 MHz, CDCl_3): δ 7.74 (d, 2H, $J = 8.4$ Hz), 7.33 (d, 2H, $J = 8.4$ Hz), 5.43 (s, 1H), 5.17 (s, 1H), 4.48 (m, 1H), 3.65 (dd, 1H, $J = 8.8, 7.2$ Hz), 3.56 (dd, 1H, $J = 11.6, 4.4$ Hz), 3.41 (d, 1H, $J = 11.6$ Hz), 3.33 (dd, 1H, $J = 11.6, 8.8$ Hz), 2.93-2.88 (m, 1H), 2.43 (s, 3H), 1.61 (brd, 1H, $J = 3.6$ Hz).

^{13}C NMR (100 MHz, CDCl_3): δ 143.7, 136.4, 133.8, 129.8, 127.5, 115.6, 70.9, 55.3, 52.2, 47.6, 21.5.

LRMS (EI) m/z (relative intensity): 301 $[\text{M}]^+$ (14), 266 (97), 244 (13), 184 (100).


HRMS (EI, $[\text{M}]^+$): calcd for $\text{C}_{13}\text{H}_{16}\text{ClNO}_3\text{S}$, 301.0539 (-)-11k; found, 301.0553.

$[\alpha]_{\text{D}}^{28} = -8.91$ ($c = 0.81$ in CHCl_3).


Chiral HPLC: (Daicel Chiralpak AD-H, *i*-propanol/hexane =10:90, 0.5 mL/min, $\lambda = 254$ nm):

$t_{\text{R}}(3R, 4R) = 20.4$ min (minor enantiomer), $t_{\text{R}}(3S, 4S) = 21.7$ min (major enantiomer).

HPLC chromatographs of **111**



Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	32.98	50.694	33.001	49.85
2	35.76	46.730	33.203	50.15




Peak	RT (time)	Hight (mV)	Area (mV*time)	Area%
1	32.70	14.610	9.150	6.62
2	35.28	180.647	129.056	93.38


Pd(II) catalyzed cyclization of allene-aldehyde to give (1R, 5R)-11f

To a test tube containing a solution of 3,3-Bis[(benzyloxy)methyl]hepta-5,6-dienal (12.6 mg, 0.036 mmol) in anhydrous MeCN (360 μ L) were added Pd(OAc)₂ (0.8 mg, 10 mol%), (*S*)-SEGPHOS (2.2 mg, 10 mol%) and PhB(OH)₂ (6.6 mg, 1.5 eq.) under argon. The resulting mixture was sealed with a screw cap and stirred at 50 °C for 2 h. Then the mixture were added CHCl₃ and *N,N*-diethanolaminomethylpolystyrene (PS-DEAMTM, 1.8 mmol/g, 3 eq.). The mixture was agitated for 2 h and then filtered and washed with CHCl₃. The filtrate was concentrated in vacuo and the residue was purified by preparative TLC to afford **(1R, 5R)-11f** (12.3 mg, 80%).

Preparation of Substrates



{[2-(*tert*-Butyldimethylsilyloxy)ethyl](toluene-4-sulfonyl)amino}acetic acid methyl ester



To a solution of *N*-[2-(*tert*-butyldimethylsilyloxy)ethyl]-4-methylbenzenesulfonamide⁶⁾ (3.00 g, 9.10 mmol) in anhydrous THF (120 mL) was added a suspension of NaH (262 mg, 10.9 mmol) in anhydrous THF (30 mL) at 0 °C, and stirred for 15 min at room temperature. Then methyl bromoacetate (0.92 mL, 10 mmol) was added to the mixture at 0 °C. The mixture was stirred at room temperature for 8 h, and then treated with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (10:1)] to afford [[2-(*tert*-butyldimethylsilyloxy)ethyl](toluene-4-sulfonyl)amino]acetic acid methyl ester (3.43 g, 94%) as a colorless oil.

$R_f = 0.63$ (9:1 toluene/EtOAc).

IR ν (neat, cm⁻¹): 2954, 2857, 1756, 1343, 1160, 1091, 937, 837, 779.

¹H NMR (400 MHz, CDCl₃): δ 7.71 (d, 2H, $J = 8.4$ Hz), 7.28 (d, 2H, $J = 8.4$ Hz), 4.24 (s, 2H), 3.76 (t, 2H, $J = 5.6$ Hz), 3.61 (s, 3H), 3.36 (t, 2H, $J = 5.6$ Hz), 2.41 (s, 3H), 0.83 (s, 9H), 0.03 (s, 6H).


¹³C NMR (100 MHz, CDCl₃): δ 169.6, 143.3, 137.0, 129.4, 127.4, 62.9, 51.9, 50.1, 49.5, 25.6, 21.5, 18.1, -5.6.

LRMS (EI) m/z (relative intensity): 386 [M-CH₃]⁺ (3), 344 (100), 286 (8), 272 (9), 256 (7), 255

(7), 155 (16).

HRMS (EI, $[M-CH_3]^+$): calcd for $C_{17}H_{28}NO_5SSi$, 386.1457; found, 386.1440.

***N*-[2-(*tert*-Butyldimethylsilanyloxy)ethyl]-4-methyl-*N*-(2-oxoethyl)benzenesulfonamide**



To a solution of [[2-(*tert*-butyldimethylsilanyloxy)ethyl](toluene-4-sulfonyl)amino]acetic acid methyl ester (3.30 g, 8.22 mmol) in anhydrous DCM (30 mL) was added DIBAL (12.3 mL of a 1.01 M solution in toluene, 12.4 mmol) dropwise at -78 °C. The mixture was stirred for 2 h at -78 °C. The mixture was allowed to warm up to room temperature, and then diluted with Et_2O , quenched with pH 6.86 phosphate buffer. The precipitate was removed by filtration through a Celite[®] pad, washed with Et_2O , and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (9:1)] to afford *N*-[2-(*tert*-butyldimethylsilanyloxy)ethyl]-4-methyl-*N*-(2-oxoethyl)benzenesulfonamide (2.47 g, 81%) as a white solid.

Mp = 62-65 °C.

R_f = 0.54 (9:1 toluene/EtOAc).

IR ν (neat, cm^{-1}): 2954, 2929, 2857, 1736, 1346, 1258, 1161, 1091, 997, 837, 780.


1H NMR (400 MHz, $CDCl_3$): δ 9.62 (s, 1H), 7.74 (d, 2H, $J = 8.4$ Hz), 7.31 (d, 2H, $J = 8.4$ Hz), 3.94 (s, 2H), 3.79 (t, 2H, $J = 5.0$ Hz), 3.31 (t, 2H, $J = 5.0$ Hz), 2.42 (s, 1H), 0.86 (s, 9H), 0.03 (s, 6H).

^{13}C NMR (100 MHz, $CDCl_3$): δ 199.1, 143.9, 136.0, 129.9, 127.2, 63.5, 58.7, 52.0, 25.8, 21.5, 18.2, -5.6 .

LRMS (EI) m/z (relative intensity): 371 $[M]^+$ (0.2), 356 (2), 342 (19), 314 (72), 272 (8), 155 (11).

HRMS (EI, $[M]^+$): calcd for $C_{17}H_{29}NO_4SSi$, 371.1587; found, 371.1591.

***N*-[2-(*tert*-Butyldimethylsilanyloxy)ethyl]-*N*-(2-hydroxy-3-phenyl-but-3-enyl)-4-methylbenzenesulfonamide**



To a solution of magnesium turnings (303 mg, 12.5 mmol) and iodine (1 crystal) in anhydrous THF (15 mL) was added 1-phenylvinyl bromide (0.81 mL, 6.24 mmol) dropwise at 0 °C. The mixture was stirred for 1 h at room temperature, before addition of a solution of *N*-[2-(*tert*-butyldimethylsilanyloxy)ethyl]-4-methyl-*N*-(2-oxoethyl)benzenesulfonamide (1.16 g,

3.12 mmol) in anhydrous THF (30 mL) dropwise at $-78\text{ }^{\circ}\text{C}$. The mixture was stirred for 1 h at $-78\text{ }^{\circ}\text{C}$. The mixture was allowed to warm up to room temperature for 2 h, and then treated with saturated aqueous NH_4Cl . The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (15:1)] to afford *N*-[2-(*tert*-butyl-dimethyl-silanyloxy)ethyl]-*N*-(2-hydroxy-3-phenyl-but-3-enyl)-4-methylbenzenesulfonamide (1.20 g, 81%) as a yellow oil.

$R_f = 0.54$ (9:1 toluene/EtOAc).

IR ν (neat, cm^{-1}): 3414, 2954, 2928, 2857, 1344, 1161, 1090, 837, 714.


^1H NMR (400 MHz, CDCl_3): δ 7.56 (d, 2H, $J = 8.4$ Hz), 7.43-7.26 (m, 5H), 7.22 (d, 2H, $J = 8.4$ Hz), 5.54 (s, 1H), 5.42 (s, 1H), 4.99 (m, 1H), 4.24 (d, 1H, $J = 1.6$ Hz), 3.99-3.94 (m, 1H), 3.83-3.78 (m, 1H), 3.46 (ddd, 1H, $J = 14.8, 5.0, 5.0$ Hz), 3.33 (d, 1H, 14.4 Hz), 3.14 (ddd, 1H, $J = 14.8, 7.2, 4.4$), 2.80 (dd, 1H, $J = 14.4, 9.6$ Hz), 2.38 (s, 3H), 0.91 (s, 9H), 0.11 (s, 6H).

^{13}C NMR (100 MHz, CDCl_3): δ 148.0, 143.4, 139.2, 135.5, 129.6, 128.4, 127.7, 127.3, 126.5, 113.7, 72.5, 63.1, 57.0, 52.9, 25.9, 21.4, 18.4, -5.5 .

LRMS (EI) m/z (relative intensity): 475 [M] $^+$ (11), 418 (26), 342 (100), 272 (44).

HRMS (EI, [M] $^+$): calcd for $\text{C}_{25}\text{H}_{37}\text{NO}_4\text{SSi}$, 475.2213; found, 475.2220.

1-(*N*-{2-[(*tert*-Butyldimethylsilyl)oxy]ethyl}(4-methylbenzene)sulfonamide)-3-phenylbut-3-en-2-yl acetate



To a solution of *N*-[2-(*tert*-butyldimethylsilanyloxy)ethyl]-*N*-(2-hydroxy-3-phenyl-but-3-enyl)-4-methylbenzenesulfonamide (1.10 g, 2.31 mmol) in anhydrous THF (15 mL) were added Et_3N (0.64 mL, 4.6 mmol), DMAP (25 mg, 0.23 mmol), and acetic anhydride (0.44 mL, 4.6 mmol). The mixture was stirred at room temperature for 1 h, and then partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (9:1)] to afford 1-(*N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}(4-methylbenzene)sulfonamide)-3-phenylbut-3-en-2-yl acetate (1.08 g, 90%) as a pale yellow oil.

$R_f = 0.70$ (2:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 2954, 2929, 2857, 1747, 1348, 1230, 1162, 1091, 837, 779.

^1H NMR (400 MHz, CDCl_3): δ 7.60 (d, 2H, $J = 8.4$ Hz), 7.46-7.29 (m, 5H), 7.23 (d, 2H, $J = 8.4$ Hz), 5.91 (dd, 1H, $J = 9.4, 3.2$ Hz), 5.38 (s, 1H), 5.32 (s, 1H), 3.66 (t, 2H, $J = 6.4$ Hz), 3.53-3.25


(m, 4H), 2.39 (s, 3H), 2.11 (s, 3H), 0.82 (s, 9H), 0.03 (s, 6H).

^{13}C NMR (100 MHz, CDCl_3): δ 169.8, 146.0, 143.2, 138.4, 137.0, 129.6, 128.5, 128.1, 127.1, 126.7, 114.5, 73.6, 61.8, 52.1, 50.6, 25.8, 21.4, 21.0, 18.1, -5.6.

LRMS (EI) m/z (relative intensity): 502 $[\text{M}-\text{CH}_3]^+$ (1.6), 460 (55), 342 (100), 314 (9), 272 (12).

HRMS (EI, $[\text{M}-\text{CH}_3]^+$): calcd for $\text{C}_{26}\text{H}_{36}\text{NO}_5\text{SSi}$, 502.2083; found, 502.2086.

1-[*N*-(2-Hydroxyethyl)(4-methylbenzene)sulfonamide]-3-phenylbut-3-en-2-yl acetate



To a solution of 1-(*N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}(4-methylbenzene)sulfonamide)-3-phenylbut-3-en-2-yl acetate (1.00 mg, 1.93 mmol) in anhydrous THF (20 mL) were added AcOH (0.11 mL, 1.9 mmol), and Bu_4NF (2.1 mL 1.0 M solution in THF, 2.1 mmol) successively. The mixture was stirred at room temperature for 3 h, and then partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (2:1)] to afford 1-[*N*-(2-hydroxyethyl)(4-methylbenzene)sulfonamide]-3-phenylbut-3-en-2-yl acetate (743 mg, 95%) as a colorless oil.

R_f = 0.39 (1:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 3534, 3026, 29.32, 1743, 1598, 1338, 1232, 1159, 1046, 755, 658.


^1H NMR (400 MHz, CDCl_3): δ 7.57 (d, 2H, J = 8.4 Hz), 7.46-7.32 (m, 5H), 7.24 (d, 2H, J = 8.4 Hz), 6.07 (brd, 2H, J = 8.0 Hz), 5.40 (s, 1H), 5.36 (s, 1H), 3.81-3.69 (m, 2H), 3.37 (dd, 1H, J = 15.4, 9.6 Hz), 3.29-3.16 (m, 3H), 2.42 (s, 3H), 2.17 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3): δ 170.4, 145.4, 143.6, 138.2, 135.4, 129.7, 128.6, 128.2, 127.2, 126.6, 114.4, 73.7, 61.1, 53.5, 53.1, 21.4, 21.1.

LRMS (EI) m/z (relative intensity): 403 $[\text{M}]^+$ (2), 342 (2), 329 (2), 269 (15), 227 (100), 155 (11).

HRMS (EI, $[\text{M}]^+$): calcd for $\text{C}_{21}\text{H}_{25}\text{O}_5\text{S}$, 403.1453; found: 403.1442.

1-[*N*-(2-Oxoethyl)(4-methylbenzene)sulfonamide]-3-phenylbut-3-en-2-yl acetate (13a)



To a solution of 1-[*N*-(2-hydroxyethyl)(4-methylbenzene)sulfonamide]-3-phenyl but-3-en-2-yl acetate (200 mg, 0.496 mmol) in anhydrous DCM (10 mL) was added Dess-Martin periodinane

(315 mg, 0.74 mmol) at 0 °C. The mixture was stirred at room temperature for 2 h, and then treated with saturated aqueous Na₂SO₃, and NaHCO₃. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (3:1)] to afford **13a** (163 mg, 82%) as a colorless oil.

R_f = 0.41 (1:1 hexane/EtOAc).

IR ν (neat, cm⁻¹): 1740, 1346, 1229, 1159, 713.


¹H NMR (400 MHz, CDCl₃): δ 9.55 (s, 1H), 7.57 (d, 2H, *J* = 8.4 Hz), 7.42-7.33 (m, 5H), 7.26 (d, 2H, *J* = 8.4 Hz), 5.87 (dd, 1H, *J* = 8.4, 2.8 Hz), 5.41 (s, 1H), 5.32 (s, 1H), 3.92 (d, 1H, *J* = 18.4 Hz), 3.75 (d, 2H, 18.4 Hz), 3.48 (dd, 1H, *J* = 15.4, 2.8 Hz), 3.22 (dd, 1H, *J* = 15.4, 8.4 Hz), 2.43 (s, 3H), 2.15 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 198.5, 169.7, 145.2, 144.1, 138.0, 135.2, 129.9, 128.7, 128.4, 127.4, 126.6, 114.8, 74.0, 58.5, 52.7, 21.5, 21.1.

LRMS (EI) *m/z* (relative intensity): 401 [M]⁺ (4), 372 (7), 359 (20), 330 (24), 246 (45), 226 (100), 155 (60).

HRMS (EI, [M]⁺): calcd for C₂₁H₂₃NO₅S, 401.1297; found, 401.1289.

***N*-{2-[(Ethoxycarbonyl)oxy]-3-phenylbut-3-en-1-yl}-2-hydroxy-*S*-(4-methylphenyl)ethane-1-sulfonamide**



To a solution of *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-2-hydroxy-*S*-(4-methylphenyl)-3-phenylbut-3-ene-1-sulfonamide (1.50 g, 3.15 mmol) in anhydrous DCM (10 mL) were added pyridine (1.52 mL, 18.9 mmol) and ethyl chloroformate (908 μL, 9.46 mmol) at 0 °C. The mixture was stirred for 2 h at the same temperature, and then treated with aqueous 3 M HCl. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The crude product was dissolved in MeOH (20 mL). To this solution was added *p*-toluenesulfonic acid monohydrate (137 mg, 0.721 mmol). The mixture was stirred at room temperature for 1 h, and then basified with saturated aqueous NaHCO₃. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (1:1)] to afford *N*-{2-[(ethoxycarbonyl)oxy]-3-phenylbut-3-en-1-yl}-2-hydroxy-*S*-(4-methylphenyl)ethane-1-sulfonamide (1.10 g, 88%) as a yellow oil.

R_f = 0.21 (2:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 3533, 2984, 2932, 1749, 1341, 1261, 1159, 1023, 714, 657.

^1H NMR (400 MHz, CDCl_3): 7.56 (d, 2H, $J = 8.4$ Hz), 7.46 (m, 2H), 7.39-7.33 (m, 3H), 7.23 (d, 2H, $J = 8.4$ Hz), 5.91 (dd, 1H, $J = 9.6, 2.8$ Hz), 5.43 (s, 1H), 5.40 (s, 1H), 4.23 (q, 2H, $J = 7.6$ Hz), 3.83-3.70 (m, 2H), 3.39-3.30 (m, 2H), 3.22 (dd, 1H, $J = 15.6, 9.6$ Hz), 3.17-3.12 (m, 1H), 2.78 (t, 1H, $J = 5.6$ Hz), 2.39 (s, 3H), 1.33 (t, 3H, $J = 7.6$ Hz)

^{13}C NMR (100 MHz, CDCl_3): 154.3, 145.3, 143.6, 138.0, 135.3, 129.7, 128.7, 128.3, 127.4, 126.6, 114.6, 78.0, 64.5, 61.2, 53.4, 53.3, 21.4, 14.2.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{26}\text{H}_{37}\text{NO}_5\text{SSiNa}$, 456.1457; found, 456.1450.

***N*-{2-[(Ethoxycarbonyloxy)-3-phenylbut-3-en-1-yl]}-*S*-(4-methylphenyl)-2-oxoethane-1-sulfonamide (13b)**



To a solution of *N*-{2-[(ethoxycarbonyloxy)-3-phenylbut-3-en-1-yl]}-2-hydroxy-*S*-(4-methylphenyl)ethane-1-sulfonamide (250 mg, 0.645 mmol) in anhydrous DCM (5.0 mL) was added Dess-Martin periodinane (328 mg, 0.774 mmol). The mixture was stirred at room temperature for 2 h, and then treated with saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$, and NaHCO_3 . The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (3:1)] to afford *N*-{2-[(ethoxycarbonyloxy)-3-phenylbut-3-en-1-yl]}-*S*-(4-methylphenyl)-2-oxoethane-1-sulfonamide (**13b**) (172 mg, 62%) as a yellow oil.

$R_f = 0.64$ (2:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 2983, 1749, 1598, 1346, 1261, 1160, 759.


^1H NMR (400 MHz, CDCl_3): δ 9.54 (s, 1H), 7.55 (d, 2H, $J = 8.4$ Hz), 7.43-7.35 (m, 5H), 7.24 (d, 2H, $J = 8.4$ Hz), 5.73 (m, 1H), 5.43 (s, 1H), 5.35 (s, 1H), 4.21 (q, 2H, $J = 7.2$ Hz), 4.03 (d, 1H, $J = 19.2$ Hz), 3.87 (d, 1H, $J = 19.2$ Hz), 3.55 (dd, 1H, $J = 15.6, 2.4$ Hz), 3.12 (dd, 1H, $J = 15.6, 8.8$ Hz), 2.41 (s, 3H), 1.32 (t, 3H, $J = 7.2$ Hz).

^{13}C NMR (100 MHz, CDCl_3): δ 197.9, 153.9, 145.1, 144.1, 137.8, 135.3, 129.8, 128.7, 128.4, 127.4, 126.6, 114.8, 78.5, 64.5, 58.9, 52.8, 21.5, 14.2.

LRMS (EI) m/z (relative intensity): 431 $[\text{M}]^+$ (1), 418 (4), 402 (6), 387 (11), 330 (17), 276 (36), 226 (98).

HRMS (EI, $[\text{M}-\text{CHO}]^+$): calcd for $\text{C}_{21}\text{H}_{24}\text{NO}_5\text{S}$, 402.1375; found, 402.1360.

1-(*N*-{2-[(*tert*-Butyldimethylsilyloxy)ethyl]}4-methylbenzenesulfonamide)-3-phenylbut-3-en-2-yl formate



To a solution of *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-2-hydroxy-*S*-(4-methylphenyl)-3-phenylbut-3-ene-1-sulfonamide (500 mg, 1.05 mmol) in anhydrous DCM (5.0 mL) were added DMAP (1 crystal) and *N*-formyl benzotriazole⁷ (232 mg, 1.58 mmol). The mixture was stirred for 2 h at room temperature, and then treated with saturated aqueous NH₄Cl. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (8:1)] to afford 1-(*N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}4-methylbenzenesulfonamide)-3-phenylbut-3-en-2-yl formate (529 mg, quant.) as a colorless oil.

R_f = 0.74 (1:1 hexane/EtOAc).


IR ν (neat, cm⁻¹): 2954, 2929, 2853, 1730, 1345, 1161, 836, 778.

¹H NMR (400 MHz, CDCl₃): δ 8.00 (s, 1H), 7.60 (d, 2H, *J*=8.4 Hz), 7.43 (m, 2H), 7.35 (m, 3H), 7.23 (d, 2H, *J*=8.4 Hz), 6.01 (m, 1H), 5.41 (s, 1H), 5.35 (s, 1H), 3.68 (dd, 2H, *J*=6.4, 6.4 Hz), 3.57 (dd, 1H, *J*=14.8, 9.2 Hz), 3.45 (dd, 1H, *J*=14.8, 2.8 Hz), 3.76 (ddd, 1H, *J*=15.2, 6.4, 6.4 Hz), 3.27 (ddd, 1H, *J*=15.2, 6.4, 6.4 Hz), 2.39 (s, 3H), 0.80 (s, 9H), -0.02 (s, 6H).

¹³C NMR (100 MHz, CDCl₃): δ 159.8, 145.4, 143.3, 138.2, 137.0, 129.6, 128.6, 128.3, 127.3, 127.2, 126.7, 73.6, 62.0, 52.2, 50.8, 25.9, 25.7, 18.1, -5.58.

HRMS (ESI, [M+Na]⁺): calcd for C₂₆H₃₇NO₅SSiNa, 526.2059; found, 526.2045.

1-[*N*-(2-Oxoethyl)4-methylbenzenesulfonamide]-3-phenylbut-3-en-2-yl formate (**13c**)



To a solution of 1-(*N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}4-methylbenzenesulfonamide)-3-phenylbut-3-en-2-yl formate (170 mg, 0.439 mmol) in THF (18 mL) were added H₂O (3.0 mL) and formic acid (9.0 mL). The mixture was stirred for 8 h at room temperature, and then treated with saturated aqueous NaHCO₃. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The crude product was dissolved in anhydrous DCM (5.0 mL). Dess-Martin periodinane (223 mg, 0.527 mmol). The mixture was stirred at room temperature for 2 h, and then treated with saturated aqueous Na₂S₂O₃, and NaHCO₃. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (3:1)] to afford 1-[*N*-(2-oxoethyl)4-methylbenzenesulfonamide]-3-phenylbut-3-en-2-yl formate (**13c**) (79.1 mg,

47%) as a yellow oil.

$R_f = 0.21$ (2:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 3027, 2977, 2929, 1729, 1598, 1495, 1344, 1162, 1090, 757.


^1H NMR (400 MHz, CDCl_3): δ 9.53 (s, 1H), 8.07 (s, 1H), 7.56 (d, 2H, $J = 8.4$ Hz), 7.41-7.33 (m, 5H), 7.25 (d, 2H, $J = 8.4$ Hz), 5.99 (dd, 1H, $J = 8.8, 2.8$ Hz), 3.97 (d, 1H, $J = 18.8$ Hz), 3.83 (d, 1H, $J = 18.8$ Hz), 3.49 (dd, 1H, $J = 15.2, 2.8$ Hz), 3.28 (dd, 1H, $J = 15.2, 8.8$ Hz), 2.45 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3): δ 197.9, 159.6, 144.5, 144.2, 137.7, 135.1, 129.8, 128.7, 128.5, 127.4, 126.6, 115.4, 73.9, 58.5, 52.6, 21.4.

LRMS (EI) m/z (relative intensity): 374 (4), 358 (4), 312 (14), 226 (91).

HRMS (EI, $[\text{M}-\text{CHO}]^+$): calcd for $\text{C}_{19}\text{H}_{20}\text{NO}_4\text{S}$, 358.1113; found, 358.1120.

***N*-[2-(*tert*-Butyldimethylsilyloxy)ethyl]-*N*-(2-hydroxybut-3-enyl)-4-methylbenzene-sulfonamide**



To a solution of *N*-[2-(*tert*-butyldimethylsilyloxy)ethyl]-4-methyl-*N*-(2-oxoethyl)-benzenesulfonamide (1.00 g, 2.69 mmol) in anhydrous THF (20 mL) was added vinylmagnesium bromide (6.7 mL of a 1.0 M solution in THF, 6.7 mL) dropwise at -78 °C, and the resulting mixture was stirred for 30 min. The mixture was allowed to warm up to room temperature for 2 h, and treated with saturated aqueous NH_4Cl . The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (10:1)] to afford *N*-[2-(*tert*-butyldimethylsilyloxy)ethyl]-*N*-(2-hydroxybut-3-enyl)-4-methylbenzenesulfonamide (909 mg, 84%) as a white solid.

$R_f = 0.44$ (9:1 toluene/EtOAc).

Mp 44-47 °C.

IR ν (neat, cm^{-1}): 3430, 2954, 2858, 1341, 1161, 1090, 837, 778.


^1H NMR (400 MHz, CDCl_3): δ 7.70 (d, 2H, $J = 8.0$ Hz), 7.31 (d, 2H, $J = 8.0$ Hz), 5.81 (ddd, 1H, $J = 17.2, 10.8, 5.6$ Hz), 5.37 (d, 2H, $J = 17.2$ Hz), 5.18 (d, 2H, $J = 10.8$ Hz), 4.44-4.36 (m, 1H), 4.03 (d, 1H, $J = 2.8$ Hz), 3.98-3.93 (m, 1H), 3.87-3.80 (m, 1H), 3.38-3.22 (m, 3H), 2.43 (s, 3H), 0.91 (s, 9H), 0.11 (s, 6H).

^{13}C NMR (100 MHz, CDCl_3): δ 143.6, 137.2, 129.9, 129.8, 127.3, 116.3, 71.9, 63.4, 56.9, 52.6, 25.9, 21.5, 18.4, -5.5 .

LRMS (EI) m/z (relative intensity): 384 $[\text{M}-\text{CH}_3]^+$ (1), 342 (100), 314 (8), 286 (3), 187 (21), 155 (9).

HRMS (EI, $[M-CH_3]^+$): calcd for $C_{18}H_{30}NO_4SSi$, 384.1665; found, 384.1648.

1-(*N*-{2-[(*tert*-Butyldimethylsilyl)oxy]ethyl}(4-methylbenzene)sulfonamide)but-3-en-2-yl formate



Acylation of *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-2-hydroxy-*S*-(4-methylphenyl)but-3-ene-1-sulfonamide (505 mg, 1.26 mmol) with *N*-formyl benzotriazole⁷ gave 1-(*N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}(4-methylbenzene)sulfonamide)but-3-en-2-yl formate (415 mg, 77%).

Column: hexane – EtOAc (15:1). Colorless oil.

R_f = 0.69 (2:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 2954, 2929, 2857, 1728, 134, 1257, 1161, 1091, 837, 779.

1H NMR (400 MHz, $CDCl_3$): δ 7.90 (s, 1H), 7.69 (d, 2H, J = 8.4 Hz), 7.28 (d, 2H, J = 8.4 Hz), 5.77 (ddd, 1H, J = 17.2, 10.0, 6.0 Hz), 5.58 (m, 1H), 5.35 (d, 1H, J = 17.2 Hz), 5.27 (d, 1H, J = 10.0 Hz), 3.72 (t, 2H, J = 5.6 Hz), 3.57 (dd, 1H, J = 14.8, 8.8 Hz), 3.47 (dd, 1H, J = 14.8, 4.8 Hz), 3.40-3.25 (m, 2H), 2.41 (s, 3H), 0.85 (s, 9H), 0.01 (s, 6H).

^{13}C NMR (100 MHz, $CDCl_3$): δ 159.9, 143.4, 137.1, 132.9, 129.6, 127.3, 119.1, 72.3, 62.3, 51.8, 50.7, 25.9, 21.5, 18.1, -5.5.

HRMS (ESI, $[M+Na]^+$): calcd for $C_{20}H_{33}NO_5SSiNa$, 450.1746; found, 450.1731.

1-[*N*-(2-Hydroxyethyl)(4-methylbenzene)sulfonamide]but-3-en-2-yl formate



Desilylation of 1-[*N*-(2-hydroxyethyl)(4-methylbenzene)sulfonamide]but-3-en-2-yl formate (400 mg, 0.935 mmol) with $HCO_2H/THF/H_2O$ gave 1-[*N*-(2-hydroxyethyl)(4-methylbenzene)sulfonamide]but-3-en-2-yl formate (93.8 mg, 32%).

Column: hexane – EtOAc (3:1). Pale yellow oil.

R_f = 0.63 (1:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 3527, 2929, 1724, 1598, 1337, 1159, 1090, 985, 661.

1H NMR (400 MHz, $CDCl_3$): δ 7.99 (s, 1H), 7.70 (d, 2H, J = 8.4 Hz), 7.32 (d, 2H, J = 8.4 Hz), 5.79 (ddd, 1H, J = 17.2, 10.4, 6.4 Hz), 5.63 (m, 1H), 5.37 (d, 1H, J = 17.2 Hz), 5.30 (d, 1H, J = 10.4 Hz), 3.77 (brs, 2H), 3.47 (dd, 1H, J = 14.8, 8.8 Hz), 3.36-3.26 (m, 3H), 2.80 (brs, 1H), 2.43 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3): δ 160.1, 143.8, 135.6, 132.6, 129.7, 127.2, 119.4, 72.6, 60.9, 52.6, 52.2, 21.4.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{14}\text{H}_{19}\text{NO}_5\text{SNa}$, 336.0882; found, 336.0875.

1-[*N*-(2-Oxoethyl)(4-methylbenzene)sulfonamide]but-3-en-2-yl formate (**13i**)



Dess-Martin oxidation of 1-[*N*-(2-hydroxyethyl)(4-methylbenzene)sulfonamide]but-3-en-2-yl formate (93.0 mg, 0.297 mmol) with *N*-formyl benzotriazole gave **13i** (55.8 mg, 60%).

Column: hexane – EtOAc (3:1). Yellow oil.

R_f = 0.43 (1:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 2951, 2932, 1728, 1345, 1231, 1161, 1090, 758.


^1H NMR (400 MHz, CDCl_3): δ 9.58 (s, 1H), 7.98 (s, 1H), 7.68 (d, 2H, J = 8.4 Hz), 7.33 (d, 2H, J = 8.4 Hz), 5.80 (ddd, 1H, J = 17.2, 10.8, 6.0 Hz), 5.33 (m, 1H), 5.37 (d, 1H, J = 17.2 Hz), 5.33 (d, 1H, J = 10.8 Hz), 3.96 (d, 1H, J = 18.8 Hz), 3.94 (d, 1H, J = 18.8 Hz), 3.47 (dd, 1H, J = 15.2, 8.0 Hz), 3.45 (dd, 1H, J = 15.2, 4.0 Hz), 2.44 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3): 197.9, 159.6, 144.3, 135.4, 132.3, 129.9, 127.4, 119.8, 72.9, 58.3, 52.5, 21.5.

LRMS (EI) m/z (relative intensity): 282 (1), 254 (29), 226 (91), 198 (8), 184 (14).

HRMS (EI, $[\text{M}-\text{CHO}]^+$): calcd for $\text{C}_{13}\text{H}_{16}\text{NO}_4\text{S}$, 282.0800; found, 282.0779.

N-{2-[(*tert*-Butyldimethylsilyloxy)ethyl]-2-hydroxy-3-methyl-*S*-(4-methylphenyl)but-3-ene-1-sulfonamide



To a solution of *N*-[2-(*tert*-butyldimethylsilyloxy)ethyl]-4-methyl-*N*-(2-oxoethyl)benzenesulfonamide (400 mg, 1.08 mmol) in anhydrous THF (10 mL) was added isopropenylmagnesium bromide solution (0.5 M in THF, 3.9 mL, 2.0 mmol) dropwise at 0 °C. The mixture was allowed to warm up to room temperature for 2 h, and then treated with saturated aqueous NH_4Cl . The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (8:1)] to afford *N*-{2-[(*tert*-butyldimethylsilyloxy)ethyl]-2-hydroxy-3-methyl-*S*-(4-methylphenyl)but-3-ene-1-sulfonamide (420 mg, 94%) as a colorless oil.

R_f = 0.58 (2:1 hexane/EtOAc).

IR ν (neat, cm⁻¹): 3511, 2954, 2929, 2858, 1342, 1257, 1160, 1090, 996, 837.


¹H NMR (400 MHz, CDCl₃): δ 7.71 (d, 2H, *J* = 8.4 Hz), 7.31 (d, 2H, *J* = 8.4 Hz), 5.05 (s, 1H), 4.89 (s, 1H), 4.30 (d, 2H, *J* = 9.6 Hz), 3.98-3.90 (m, 2H), 3.82 (ddd, 1H, *J* = 10.4, 5.2, 5.2 Hz), 3.44-3.34 (m, 2H), 3.25 (ddd, 1H, *J* = 14.8, 7.2, 4.4 Hz), 2.98 (dd, 1H, *J* = 14.4, 9.6 Hz), 2.43 (s, 3H), 1.74 (s, 3H), 0.93 (s, 9H), 0.12 (s, 6H).

¹³C NMR (100 MHz, CDCl₃): δ 144.4, 143.5, 136.0, 129.8, 127.3, 112.0, 74.4, 63.2, 56.2, 52.5, 25.9, 21.5, 18.6, 18.4, 14.2, -5.48, -5.46.

LRMS (EI) *m/z* (relative intensity): 413 [M]⁺ (1), 398 (1), 356 (28), 342 (100).

HRMS (EI, [M]⁺): calcd for C₂₀H₃₅NO₄SSi, 413.2056; found, 413.2048.

1-(*N*-{2-[(*tert*-Butyldimethylsilyloxy)ethyl]}(4-methylbenzene)sulfonamide)-3-methylbut-3-en-2-yl formate



Acylation of *N*-{2-[(*tert*-butyldimethylsilyloxy)ethyl]}-2-hydroxy-3-methyl-*S*-(4-methylphenyl)but-3-ene-1-sulfonamide (658 mg, 1.59 mmol) with *N*-formyl benzotriazole⁷⁾ gave 1-(*N*-{2-[(*tert*-butyldimethylsilyloxy)ethyl]}(4-methylbenzene)sulfonamide)-3-methylbut-3-en-2-yl formate (649 mg, 92%).

Column: hexane – EtOAc (8:1). Colorless oil.

R_f = 0.70 (2:1 hexane/EtOAc).


IR ν (neat, cm⁻¹): 2954, 2929, 2857, 1730, 1343, 1257, 1161, 1091, 837.

¹H NMR (400 MHz, CDCl₃): δ 7.88 (s, 1H), 7.69 (d, 2H, *J* = 8.4 Hz), 7.27 (d, 2H, *J* = 8.4 Hz), 5.43 (dd, 1H, *J* = 8.4, 4.4 Hz), 5.01 (s, 1H), 4.97 (s, 1H), 3.71 (dd, 2H, *J* = 6.4, 6.4 Hz), 3.58 (dd, 1H, *J* = 15.2, 8.4 Hz), 3.51 (dd, 1H, *J* = 15.2, 4.4 Hz), 3.37 (dt, 1H, *J* = 14.8, 6.4 Hz), 3.28 (dt, 1H, *J* = 14.8, 6.4 Hz), 2.40 (s, 3H), 1.75 (s, 3H), 0.84 (s, 9H), 0.01 (s, 6H).

¹³C NMR (100 MHz, CDCl₃): δ 159.8, 143.4, 140.3, 137.3, 129.6, 127.2, 114.7, 75.1, 62.3, 51.1, 50.4, 25.8, 21.4, 12.4, 18.2, -5.5.

HRMS (ESI, [M+Na]⁺): calcd for C₂₁H₃₅NO₅SSiNa, 464.1903; found, 464.1886.

1-[*N*-(2-Hydroxyethyl)(4-methylbenzene)sulfonamide]-3-methylbut-3-en-2-yl formate



Desilylation of 1-(*N*-{2-[(*tert*-butyldimethylsilyloxy)ethyl]}(4-methylbenzene)sulfonamide)-3-

methylbut-3-en-2-yl formate (630 mg, 1.42 mmol) with HCO₂H/THF/H₂O gave 1-[*N*-(2-hydroxyethyl)(4-methylbenzene)sulfonamide]-3-methylbut-3-en-2-yl formate (384 mg, 82%).

Column: hexane – EtOAc (2:1). Colorless oil.

R_f = 0.09 (2:1 hexane/EtOAc).


IR ν (neat, cm⁻¹): 3530, 2932, 1726, 1597, 1338, 1160, 1090, 754, 655.

¹H NMR (400 MHz, CDCl₃): δ 7.98 (s, 1H), 7.70 (d, 2H, *J* = 8.4 Hz), 7.32 (d, 2H, *J* = 8.4 Hz), 5.51 (dd, 1H, *J* = 8.8, 4.0 Hz), 5.06 (s, 1H), 5.01 (s, 1H), 3.83-3.74 (m, 2H), 3.46 (dd, 1H, *J* = 15.2, 8.8 Hz), 3.38 (dd, 1H, *J* = 15.2, 4.0 Hz), 3.32-3.30 (m, 2H), 2.43 (s, 3H), 1.78 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 160.0, 143.8, 140.1, 135.7, 129.7, 127.3, 114.9, 75.4, 61.1, 52.3, 52.1, 21.5, 18.4.

HRMS (ESI, [M+Na]⁺): calcd for C₁₅H₂₁NO₅SNa, 350.1038 found, 350.1022.

3-Methyl-1-[*N*-(2-oxoethyl)(4-methylbenzene)sulfonamide]but-3-en-2-yl formate (**13j**)



Dess-Martin oxidation of 1-[*N*-(2-hydroxyethyl)(4-methylbenzene)sulfonamide]-3-methylbut-3-en-2-yl formate (281 mg, 0.857 mmol) gave **13j** (177 mg, 64%).

Column: hexane – EtOAc (3:1). Pale yellow oil.

R_f = 0.63 (1:1 hexane/EtOAc).


IR ν (neat, cm⁻¹): 2925, 1728, 1344, 1160, 1090, 657.

¹H NMR (400 MHz, CDCl₃): δ 9.58 (dd, 1H, *J* = 1.2, 1.2 Hz), 7.97 (s, 1H), 7.68 (d, 2H, *J* = 8.4 Hz), 7.33 (d, 2H, *J* = 8.4 Hz), 5.38 (dd, 1H, *J* = 8.0, 4.0 Hz), 5.03 (s, 1H), 5.02 (s, 1H), 3.97 (dd, 1H, *J* = 19.2, 1.2 Hz), 3.86 (dd, 1H, *J* = 19.2, 1.2 Hz), 3.47 (dd, 1H, *J* = 15.2, 4.0 Hz), 3.40 (dd, 1H, 15.2, 8.0 Hz), 2.44 (s, 3H), 1.78 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 198.0, 159.6, 144.3, 139.7, 135.3, 130.0, 127.4, 115.0, 75.5, 58.1, 51.6, 21.6, 18.5.

HRMS (ESI, [M+Na]⁺): calcd for C₁₅H₁₉NO₅SNa, 348.0882; found, 348.0868.

N-{2-[(*tert*-Butyldimethylsilyl)oxy]ethyl}-2-hydroxy-*S*-(4-methylphenyl)-3-(trimethylsilyl)-but-3-ene-1-sulfonamide



To a suspension of magnesium turnings (78.5 mg, 3.23 mmol) and 1,2-dibromoethane (13.7 μL,

0.161 mmol) in anhydrous THF (5.0 mL) was added (1-bromovinyl)trimethylsilane (0.33 mL, 2.2 mmol) dropwise at 0 °C. The mixture was refluxed for 10 min with stirring and left to stir at room temperature for 2 h. To the mixture was added *N*-[2-(*tert*-butyldimethylsilyloxy)ethyl]-4-methyl-*N*-(2-oxoethyl)benzenesulfonamide solution (400 mg, 1.08 mmol) in anhydrous THF (10 mL) slowly. The mixture was stirred for 1 h at room temperature, and then treated with saturated aqueous NH₄Cl. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (15:1)] to afford *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-2-hydroxy-*S*-(4-methylphenyl)-3-(trimethylsilyl)but-3-ene-1-sulfonamide (452 mg, 89%) as a pale yellow oil.

R_f = 0.76 (2:1 hexane/EtOAc).

IR ν (neat, cm⁻¹): 3413, 2954, 2929, 2860, 1344, 1251, 1160, 1090, 838.


¹H NMR (400 MHz, CDCl₃): δ 7.69 (d, 2H, *J* = 8.0 Hz), 7.30 (d, 2H, *J* = 8.0 Hz), 5.84 (dd, 1H, *J* = 2.4, 1.2 Hz), 5.46 (dd, 1H, *J* = 2.4, 1.2 Hz), 4.55 (m, 1H), 4.01 (brs, 1H), 3.97 (m, 1H), 3.82 (ddd, 1H, *J* = 10.0, 5.2, 4.4 Hz), 3.40 (ddd, 1H, *J* = 15.2, 5.2, 4.8 Hz), 3.28 (dd, 1H, *J* = 14.4, 2.0 Hz), 2.81 (dd, 1H, *J* = 14.4, 10.0 Hz), 2.42 (s, 3H), 0.90 (s, 9H), 0.14 (s, 9H), 0.10 (s, 6H).

¹³C NMR (100 MHz, CDCl₃): δ 152.9, 144.3, 136.7, 130.5, 128.1, 126.1, 75.2, 64.1, 58.7, 53.5, 26.7, 22.3, 19.2, 0.00, -4.64, -4.68.

LRMS (EI) *m/z* (relative intensity): 456 [M-CH₃]⁺ (7), 414 (27), 342 (100).

HRMS (EI, [M-CH₃]⁺): calcd. for C₂₁H₃₈NO₄SSi₂, 456.2060; found, 456.2060.

1-(*N*-{2-[(*tert*-Butyldimethylsilyl)oxy]ethyl}(4-methylbenzene)sulfonamide)-3-(trimethylsilyl)but-3-en-2-yl formate



Acylation of *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-2-hydroxy-*S*-(4-methylphenyl)-3-(trimethylsilyl)but-3-ene-1-sulfonamide (600 mg, 1.27 mmol) with *N*-formyl benzotriazole⁷ gave 1-(*N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}(4-methylbenzene)sulfonamide)-3-(trimethylsilyl)but-3-en-2-yl formate (532 mg, 84%).

Column: hexane – EtOAc (8:1). White solid.

R_f = 0.79 (2:1 hexane/EtOAc).

mp = 40-41 °C.

IR ν (neat, cm⁻¹): 2955, 2929, 2857, 1730, 1343, 1252, 1159, 1091, 839.


¹H NMR (400 MHz, CDCl₃): δ 7.85 (s, 1H), 7.69 (d, 2H, *J* = 8.4 Hz), 7.28 (d, 2H, *J* = 8.4 Hz), 5.82 (s, 1H), 5.63 (dd, 1H, *J* = 9.6, 4.0 Hz), 5.51 (s, 1H), 3.57 (dd, 2H, *J* = 6.4, 6.4 Hz),

3.52-3.31 (m, 4H), 2.41 (s, 3H), 0.86 (s, 9H), 0.17 (s, 9H), 0.02 (s, 6H).

^{13}C NMR (100 MHz, CDCl_3): δ 159.9, 148.3, 143.3, 137.5, 129.6, 127.6, 127.2, 76.0, 62.2, 53.0, 50.8, 25.8, 21.5, 18.2, -1.03, -5.49.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{23}\text{H}_{41}\text{NO}_5\text{SSi}_2\text{Na}$, 522.2142; found, 522.2120.

1-[N-(2-Hydroxyethyl)(4-methylbenzene)sulfonamide]-3-(trimethylsilyl)but-3-en-2-yl formate



Desilylation of 1-[N-{2-[(*tert*-Butyldimethylsilyl)oxy]ethyl}(4-methylbenzene)sulfonamide)-3-(trimethylsilyl)but-3-en-2-yl formate (510 mg, 1.02 mmol) with $\text{HCO}_2\text{H}/\text{THF}/\text{H}_2\text{O}$ gave 1-[N-(2-hydroxyethyl)(4-methylbenzene)sulfonamide]-3-(trimethylsilyl)but-3-en-2-yl formate (367 mg, 93%).

Column: hexane – EtOAc (4:1). Colorless oil.

R_f = 0.32 (2:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 3518, 2954, 1726, 1338, 1250, 1159, 1089, 841.

^1H NMR (400 MHz, CDCl_3): δ 7.92 (s, 1H), 7.68 (d, 2H, J = 8.4 Hz), 7.30 (d, 2H, J = 8.4 Hz), 5.85 (s, 1H), 5.72 (dd, 1H, J = 9.6, 2.0 Hz), 5.53 (s, 1H), 3.84-3.73 (m, 2H), 3.40-3.26 (m, 4H), 2.63 (brs, 1H), 2.41 (s, 3H), 0.17 (s, 9H).

^{13}C NMR (100 MHz, CDCl_3): δ 160.1, 148.0, 143.8, 136.0, 129.8, 127.8, 127.3, 75.9, 61.2, 53.9, 52.5, 21.5, -1.1.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{17}\text{H}_{27}\text{NO}_5\text{SSiNa}$, 408.1277; found, 408.1259.

1-[N-(2-Oxoethyl)(4-methylbenzene)sulfonamide]-3-(trimethylsilyl)but-3-en-2-yl formate (13k)



Dess-Martin oxidation of 1-[N-(2-hydroxyethyl)(4-methylbenzene)sulfonamide]-3-(trimethylsilyl)but-3-en-2-yl formate (340 mg, 0.882 mmol) gave **13k** (272 mg, 80%).

Column: hexane – EtOAc (2:1). Colorless oil.

R_f = 0.65 (1:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 2951, 1728, 1346, 1251, 1160, 842.


^1H NMR (400 MHz, CDCl_3): δ 9.58 (s, 1H), 7.94 (s, 1H), 7.67 (d, 2H, J = 8.4 Hz), 7.33 (d, 2H, J = 8.4 Hz), 5.81 (s, 1H), 5.91 (brd, 1H, J = 10.0 Hz), 5.54 (s, 1H), 4.06 (d, 1H, J = 18.8 Hz),

3.89 (d, 1H, $J = 18.8$ Hz), 3.44 (dd, 1H, $J = 15.2, 2.4$ Hz), 3.18 (dd, 1H, $J = 15.2, 10.0$ Hz), 2.44 (s, 3H), 0.18 (s, 9H).


^{13}C NMR (100 MHz, CDCl_3): δ 198.0, 159.6, 147.7, 144.2, 135.6, 129.9, 127.7, 127.3, 76.1, 58.4, 53.5, 21.5, -1.2.

LRMS (EI) m/z (relative intensity): 368 (4), 354 (14), 326 (4), 248 (24), 226 (100).

HRMS (EI, $[\text{M}-\text{CHO}]^+$): calcd for $\text{C}_{16}\text{H}_{24}\text{NO}_5\text{SSi}$, 354.1195; found, 354.1187.



***tert*-Butyl *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-*N*-(2-hydroxy-3-phenylbut-3-en-1-yl) carbamate**



Alkenylation of *tert*-butyl *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-*N*-(2-oxoethyl)carbamate⁸²⁾ (1.16 g, 3.12 mmol) with α -styryl Grignard reagent gave *tert*-butyl *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-*N*-(2-hydroxy-3-phenylbut-3-en-1-yl)carbamate (794 mg, 50%).

Column: hexane – EtOAc (15:1). Yellow oil.

$R_f = 0.44$ (4:1 toluene/EtOAc).

IR ν (neat, cm^{-1}): 3428, 2956, 2929, 2858, 1698, 1674, 1472, 1409, 1366, 1252, 1173, 1104, 836, 778.


^1H NMR (400 MHz, CDCl_3): mixture of rotamers: δ 7.38-7.33 (m, 2H), 7.32-7.26 (m, 3H), 5.51 (brs, 1H), 5.39 (s, 1H), 4.88 (brs, 1H), 4.75 (brs, 0.6H), 4.45 (brs, 0.4H), 4.07 (m, 0.4H), 3.75-3.64 (m, 2.6H), 3.44 (m, 0.6H), 3.32 (dd, 0.6H, $J = 14.4, 8.0$ Hz), 3.19 (m, 1.4H), 2.85 (dd, 0.4H, $J = 14.4, 9.6$ Hz), 1.47 (s, 5.4H), 1.42 (s, 3.6H), 0.91 (s, 3.6H), 0.83 (s, 5.4H), 0.10 (s, 2.4H), 0.07 (s, 3.6H).

^{13}C NMR (100 MHz, CDCl_3): δ 157.8, 155.5, 149.1, 139.8, 128.4, 128.3, 127.6, 126.7, 126.6, 113.7, 113.4, 80.5, 80.2, 73.5, 72.9, 61.9, 61.7, 57.0, 55.7, 52.3, 51.7, 28.4, 25.9, 25.9, -5.5, -5.5.

LRMS (EI) m/z (relative intensity): 322 $[\text{M}]^+$ (0.1), 279 (1), 265 (13).

HRMS (EI, $[M]^+$): calcd for $C_{18}H_{30}NO_3Si$, 322.1964; found, 322.1954.

1- $\{[(tert\text{-}Butoxy)carbonyl](2\text{-hydroxyethyl})amino\}$ -3-phenylbut-3-en-2-yl acetate



To a solution of *tert*-butyl *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-*N*-(2-hydroxy-3-phenylbut-3-en-1-yl)carbamate (400 mg, 1.24 mmol) in anhydrous THF (5.0 mL) were added Et_3N (345 μ L, 2.48 mmol), DMAP (1 crystal) and Ac_2O (234 μ L, 2.48 mmol). The mixture was stirred at room temperature for 1 h, and then treated with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over $MgSO_4$, and concentrated *in vacuo*. The crude product was dissolved in DCM/MeOH (9:1, 10 mL). To this solution was added CSA (110 mg, 0.47 mmol). The mixture was stirred at room temperature for 1 h, and then treated with saturated aqueous $NaHCO_3$. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (2:1)] to afford 1- $\{[(tert\text{-}butoxy)carbonyl](2\text{-hydroxyethyl})amino\}$ -3-phenylbut-3-en-2-yl acetate (266 mg, 80%) as a colorless oil.

R_f = 0.23 (2:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 3480, 2977, 1739, 1691, 1409, 1363, 1232, 773.


1H NMR (400 MHz, $CDCl_3$): mixture of rotamers: δ 7.46 (d, 2H, J = 6.0 Hz), 7.36-7.29 (m, 3H), 6.07 (brs, 0.3H), 5.90 (d, 0.7H, J = 7.6 Hz), 5.42-5.36 (m, 1.3H), 5.31 (s, 0.7H), 3.71 (m, 2.0H), 3.59-3.50 (m, 1.3H), 3.39-3.37 (m, 1H), 3.26-3.20 (m, 1H), 3.08 (m, 0.7H), 2.14 (s, 3H), 1.38 (s, 9H).

^{13}C NMR (100 MHz, $CDCl_3$): mixture of rotamers: δ 169.9, 156.8, 146.6, 138.8, 128.5, 128.1, 126.7, 114.2, 80.8, 74.5, 73.6, 62.2, 52.4, 51.8, 28.2, 21.1.

LRMS (EI) m/z (relative intensity): 349 $[M]^+$ (1), 293 (3), 249 (21), 233 (42).

HRMS (EI, $[M]^+$): calcd for $C_{19}H_{27}NO_5$, 349.1889; found, 349.1880.

1- $\{[(tert\text{-}Butoxy)carbonyl](2\text{-oxoethyl})amino\}$ -3-phenylbut-3-en-2-yl acetate (**13d**)



Dess-Martin oxidation of 1- $\{[(tert\text{-}butoxy)carbonyl](2\text{-hydroxyethyl})amino\}$ -3-phenylbut-3-en-2-yl acetate (100 mg, 0.286 mmol) gave **13d** (80.9 mg, 82%).

Column: hexane – EtOAc (6:1). Pale yellow oil.

$R_f = 0.67$ (2:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 2981, 2936, 1743, 1699, 1369, 1230, 1165, 1147, 1036, 762.


^1H NMR (400 MHz, CDCl_3): mixture of rotamers: δ 9.51 (s, 0.6H), 9.48 (s, 0.4H), 7.46-7.45 (m, 2H), 7.37-7.27 (m, 3H), 5.89 (dd, 0.4H, $J = 8.8, 3.6$ Hz), 5.83 (dd, 0.6H, $J = 8.8, 3.6$ Hz), 5.04 (s, 0.4H), 5.36 (s, 0.6H), 5.35 (s, 0.4H), 5.28 (s, 6H), 3.99 (s, 1H), 3.90-3.66 (m, 2H), 3.39 (dd, 0.4H, $J = 14.8, 8.8$ Hz), 3.15 (dd, 0.4H, $J = 14.8, 8.8$ Hz), 2.12 (s, 1.8H), 2.10 (s, 1.2H), 1.40 (s, 3.6H), 1.37 (s, 5.4H).

^{13}C NMR (100 MHz, CDCl_3): mixture of rotamers: δ 199.1, 198.8, 169.9, 169.8, 155.3, 154.7, 146.3, 145.9, 138.6, 138.5, 128.6, 128.5, 128.2, 128.2, 126.7, 126.6, 114.6, 114.1, 81.3, 81.2, 74.9, 73.9, 58.7, 52.3, 52.0, 28.1, 28.1, 21.1.

LRMS (EI) m/z (relative intensity): 347 [M] $^+$ (1), 303 (2), 291 (20), 249 (50), 231 (50).

HRMS (EI, [M] $^+$): calcd for $\text{C}_{19}\text{H}_{25}\text{NO}_5$, 347.1733; found, 347.1729.

1-{2-[(*tert*-Butyldimethylsilyloxy)ethoxy]-3-phenylbut-3-en-2-ol



Alkenylation of 2-{2-[(*tert*-butyldimethylsilyloxy)ethoxy]acetaldehyde²⁾ (960 mg, 4.36 mmol) with α -styryl Grignard reagent gave 1-{2-[(*tert*-butyldimethylsilyloxy)ethoxy]-3-phenylbut-3-en-2-ol (733 mg, 52%).

Column: hexane – EtOAc (15:1). Yellow oil.

$R_f = 0.46$ (4:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 3447, 2954, 2928, 2857, 1472, 1255, 1138, 1105, 836, 777.


^1H NMR (400 MHz, CDCl_3): δ 7.38-7.26 (m, 5H), 5.51 (s, 1H), 5.39 (s, 1H), 4.85 (d, 1H, $J = 8.4$ Hz), 3.75 (t, 2H, $J = 8.4$ Hz), 3.61-3.54 (m, 4H), 3.32 (dd, 1H, $J = 10.0, 8.4$ Hz), 0.89 (s, 9H), 0.07 (s, 6H).

^{13}C NMR (100 MHz, CDCl_3): δ 147.5, 139.8, 128.3, 127.6, 126.6, 113.8, 75.0, 72.7, 72.1, 62.7, 25.9, 18.3, -5.3.

LRMS (EI) m/z (relative intensity): 322 [M] $^+$ (0.1), 279 (1), 265 (13).

HRMS (EI, [M] $^+$): calcd for $\text{C}_{18}\text{H}_{30}\text{O}_3\text{Si}$, 322.1964 found, 322.1954.

1-(2-Hydroxyethoxy)-3-phenylbut-3-en-2-yl acetate



To a solution of 1-{2-[(*tert*-butyldimethylsilyloxy)ethoxy]-3-phenylbut-3-en-2-ol (400 mg,

0.949 mmol) in anhydrous THF (5 mL) were added Et₃N (264 μ l, 1.90 mmol), DMAP (1 crystal) and Ac₂O (179 μ l, 1.90 mmol). The mixture was stirred at room temperature for 1 h, and then treated with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The crude product was dissolved in MeOH (10 mL). Then to this solution was added *p*-toluenesulfonic acid monohydrate (59.0 mg, 0.310 mmol). The mixture was stirred at room temperature for 1 h, and then basified with saturated aqueous NaHCO₃. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (2:1)] to afford 1-(2-hydroxyethoxy)-3-phenylbut-3-en-2-yl acetate (196 mg, 63%) as a colorless oil.

R_f = 0.25 (2:1 hexane/EtOAc).

IR ν (neat, cm⁻¹): 3447, 2933, 2870, 1742, 1374, 1236, 1132, 1052, 779.


¹H NMR (400 MHz, CDCl₃): δ 7.43 (d, 2H, *J* = 6.8 Hz), 7.37-7.31 (m, 3H), 5.91 (dd, 1H, *J* = 7.6, 3.2 Hz), 5.38 (s, 1H), 5.35 (s, 1H), 3.65-3.47 (m, 6H), 2.16 (s, 3H), 2.04 (br s, 1H).

¹³C NMR (100 MHz, CDCl₃): δ 170.3, 145.4, 139.0, 128.5, 128.1, 126.7, 114.7, 74.1, 72.4, 72.2, 61.6, 21.2.

LRMS (EI) *m/z* (relative intensity): 251 [M+H]⁺ (0.1), 219 (1), 190 (60).

HRMS (EI, [M]⁺): calcd for C₂₄H₁₈O₄, 250.1205; found, 250.1329.

1-(2-Oxoethoxy)-3-phenylbut-3-en-2-yl acetate (**13e**)



Dess-Martin oxidation of 1-(2-hydroxyethoxy)-3-phenylbut-3-en-2-yl acetate (100 mg, 0.403 mmol) gave **13e** (57.0 mg, 58%).

Column: hexane – EtOAc (6:1). Colorless oil.

R_f = 0.31 (2:1 hexane/EtOAc).


IR ν (neat, cm⁻¹): 2928, 2871, 1739, 1375, 1234, 1139, 1051, 780, 702.

¹H NMR (400 MHz, CDCl₃): δ 9.64 (dd, 1H, *J* = 0.8, 0.8 Hz), 7.45-7.41 (m, 2H), 7.37- 7.29 (m, 3H), 5.94 (m, 1H), 5.39 (s, 1H), 5.36 (s, 1H), 4.08 (dd, 2H, *J* = 17.6, 0.8 Hz), 4.02 (dd, 2H, *J* = 17.6, 0.8 Hz), 3.64 (m, 2H), 2.16 (s, 3H).


¹³C NMR (100 MHz, CDCl₃): δ 200.3, 170.1, 145.0, 138.8, 128.5, 128.2, 126.7, 114.9, 76.4, 74.0, 72.7, 21.1.

LRMS (EI) *m/z* (relative intensity): 248 [M]⁺ (0.1), 219 (1), 188 (100).

HRMS (EI, [M]⁺): calcd for C₁₄H₁₆O₄, 248.1049; found, 248.1020.



[(2-[(Benzyloxy)methyl]-2-(2,2-dimethoxyethyl)pent-4-en-1-yl)oxy)methyl]benzene



[(2-[(Benzyloxy)methyl]-2-(2,2-dimethoxyethyl)pent-4-en-1-yl)oxy)methyl]benzene was prepared according to the modified literature procedure⁹ using allyl bromide instead of 1-bromo-2-butyne.

Colorless oil.

$R_f = 0.50$ (4:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 2928, 2858, 1454, 1364, 1116, 1100, 1076, 736, 698.

^1H NMR (400 MHz, CDCl_3): δ 7.31-7.26 (m, 10H), 5.80 (ddt, 1H, $J = 17.2, 10.4, 7.2$ Hz), 5.07-5.02 (m, 2H), 4.57 (t, 1H, $J = 5.2$ Hz), 4.47 (s, 4H), 3.36 (s, 4H), 3.25 (s, 6H), 2.21 (d, 2H, $J = 7.2$ Hz), 1.68 (d, 2H, $J = 5.2$ Hz).

^{13}C NMR (100 MHz, CDCl_3): δ 138.8, 134.4, 128.2, 127.4, 127.3, 117.8, 102.3, 73.1, 72.9, 52.5, 40.6, 37.4, 35.1.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{24}\text{H}_{32}\text{O}_4\text{Na}$, 407.2198; found, 407.2181.

3,3-Bis(benzyloxymethyl)-5,5-dimethoxypentanal



To a solution of [(2-[(benzyloxy)methyl]-2-(2,2-dimethoxyethyl)pent-4-en-1-yl)oxy)methyl]benzene (1.50 g, 3.90 mmol) in THF/*t*-BuOH/ H_2O (1:1:1, 60 mL) was added OsO_4 solution (0.05 M in THF, 3.90 mL, 0.195 mmol). The mixture was stirred for 30 min at room

temperature before addition of NaIO₄ (2.09 g, 9.75 mmol). The mixture was stirred for 1.5 h at room temperature, and then diluted with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (8:1)] to afford 3,3-bis(benzyloxymethyl)-5,5-dimethoxy-pentanal (932 mg, 60%) as a colorless oil.

R_f = 0.47 (2:1 hexane/EtOAc).

IR ν (neat, cm⁻¹): 2932, 2860, 1708, 1454, 1114, 1098, 1076, 737, 698.


¹H NMR (400 MHz, CDCl₃): δ 9.78 (t, 1H, *J* = 2.4 Hz), 7.34-7.25 (m, 10H), 4.50 (t, 1H, *J* = 5.6 Hz), 4.46 (s, 4H), 3.48 (d, 2H, *J* = 9.2 Hz), 3.43 (d, 2H, *J* = 9.2 Hz), 3.24 (s, 6H), 2.48 (d, 2H, *J* = 2.4 Hz), 1.84 (d, 2H, *J* = 5.6 Hz).

¹³C NMR (100 MHz, CDCl₃): δ 202.1, 138.1, 128.3, 127.5, 127.5, 102.1, 73.3, 73.2, 52.6, 47.4, 41.0, 35.8.

LRMS (EI) *m/z* (relative intensity): 354 (2), 323 (4), 278 (23).

HRMS (EI, [M-MeOH]⁺): calcd for C₂₂H₂₆O₄, 354.1831; found, 354.1826.

5,5-Bis(benzyloxymethyl)-7,7-dimethoxy-2-phenylhept-1-en-3-ol



Alkenylation of 3,3-bis(benzyloxymethyl)-5,5-dimethoxy-pentanal (930 mg, 2.41 mmol) with α-styryl Grignard reagent gave 5,5-bis(benzyloxymethyl)-7,7-dimethoxy-2-phenylhept-1-en-3-ol (916 mg, 67%).

Column: hexane – EtOAc (8:1). Yellow oil.

R_f = 0.50 (2:1 hexane/EtOAc).

IR ν (neat, cm⁻¹): 3433, 2929, 2861, 1454, 1365, 1115, 1075, 1028, 737, 698.


¹H NMR (400 MHz, CDCl₃): δ 7.34-7.21 (m, 15H), 5.41 (s, 1H), 5.24 (s, 1H), 4.77 (m, 1H), 4.51 (m, 1H), 4.47-4.45 (m, 4H), 4.38 (dd, 1H, *J* = 6.4, 4.4 Hz), 3.47 (d, 1H, *J* = 9.2 Hz), 3.40 (d, 1H, *J* = 9.2 Hz), 3.19 (s, 3H), 3.16 (s, 3H), 1.83 (dd, 1H, *J* = 14.8, 6.4 Hz), 1.72 (m, 2H), 1.46 (dd, 2H, *J* = 14.8, 10.0 Hz).

¹³C NMR (100 MHz, CDCl₃): δ 152.9, 140.4, 137.9, 128.3, 128.3, 128.1, 127.6, 127.6, 127.6, 127.2, 126.9, 111.8, 102.1, 73.7, 73.4, 73.3, 73.3, 69.4, 53.1, 52.0, 41.1, 40.2, 35.5.

LRMS (EI) *m/z* (relative intensity): 458 [M-MeOH]⁺ (11), 426 (14), 335 (64).

HRMS (EI, [M-MeOH]⁺): calcd for C₃₀H₃₄O₄, 458.2457; found, 458.2463.

5,5-Bis(benzyloxymethyl)-7,7-dimethoxy-2-phenylhept-1-en-3-yl acetate



Acetylation of 5,5-bis(benzyloxymethyl)-7,7-dimethoxy-phenylhept-1-en-3-ol (400 mg, 0.815mmol) with Ac₂O from gave 5,5-bis(benzyloxymethyl)-7,7-dimethoxy-2-phenylhept-1-en-3-yl acetate (391 mg, 90%).

Column: hexane – EtOAc (8:1). Yellow oil.

R_f = 0.63 (2:1 hexane/EtOAc).

IR ν (neat, cm⁻¹): 2931, 2858, 1739, 1454, 1367, 1237, 1119, 1099, 1076, 698.


¹H NMR (400 MHz, CDCl₃): δ 7.43-7.41 (m, 2H), 7.31-7.20 (m, 13H), 5.91 (d, 1H, *J* = 9.6 Hz), 5.21 (s, 1H), 5.20 (s, 1H), 4.49 (t, 1H, *J* = 5.2 Hz), 4.46-4.38 (m, 4H), 3.41-3.31 (m, 4H), 3.19 (s, 3H), 3.14 (s, 3H), 2.00 (s, 3H), 1.91 (dd, 1H, *J* = 15.2, 9.6 Hz), 1.74-1.70 (m, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 170.0, 150.3, 139.2, 138.5, 138.5, 128.2, 128.2, 127.6, 127.4, 127.3, 127.0, 112.4, 102.0, 73.1, 73.1, 73.1, 72.8, 72.7, 52.4, 51.9, 40.3, 37.4, 35.2, 21.3.

LRMS (EI) *m/z* (relative intensity): 532 [M]⁺ (0.3), 500 (2), 442 (41).

HRMS (EI, [M]⁺): calcd for C₃₃H₄₀O₆, 532.2825; found, 532.2811.

5,5-Bis(benzyloxymethyl)-7-oxo-2-phenylhept-1-en-3-yl acetate (13f)



To a solution of 5,5-bis(benzyloxymethyl)-7,7-dimethoxy-2-phenylhept-1-en-3-yl acetate (150 mg, 0.282 mmol) in AcOH/THF/H₂O (1:1:1, 1.2 mL) was added 3 M HCl aq. (one drop). The mixture was stirred at room temperature for 4 h, and then basified with saturated aqueous NaHCO₃. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (3:1)] to afford 5,5-bis(benzyloxymethyl)-7-oxo-2-phenylhept-1-en-3-yl acetate (**13f**) (128 mg, 94%) as a yellow oil.

R_f = 0.69 (4:1 toluene/EtOAc).


IR ν (neat, cm⁻¹): 3030, 2859, 1740, 1717, 1368, 1233, 1096, 1027, 698.

¹H NMR (400 MHz, CDCl₃): δ 9.74 (t, 1H, *J* = 2.4 Hz), 7.40-7.38 (m, 2H), 7.33-7.20 (m, 13H), 5.87 (dd, 1H, *J* = 10.0, 1.6 Hz), 5.24 (s, 1H), 5.19 (s, 1H), 4.41 (m, 4H), 3.47-3.37 (m, 4H), 2.45 (dd, 1H, *J* = 15.6, 2.4 Hz), 2.40 (dd, 1H, 15.6, 2.4 Hz), 2.01 (s, 3H), 1.97 (dd, 1H, *J* = 15.2, 10.0 Hz), 1.83 (dd, 1H, *J* = 15.2, 1.6 Hz).


^{13}C NMR (100 MHz, CDCl_3): 201.6, 175.1, 169.9, 149.7, 138.9, 138.0, 128.4, 128.3, 127.9, 127.6, 127.5, 127.5, 126.9, 112.7, 73.3, 73.1, 73.1, 72.6, 72.5, 47.6, 41.9, 37.7, 21.3.

LRMS (EI) m/z (relative intensity): 486 $[\text{M}]^+$ (0.1), 426 (11), 395 (7), 335 (37).

HRMS (EI, $[\text{M}]^+$): calcd for $\text{C}_{31}\text{H}_{34}\text{O}_5$, 486.2406; found, 486.02419.



[({2-[(Benzyloxy)methyl]-2-(2,2-dimethoxyethyl)pent-4-yn-1-yl}oxy)methyl]benzene



[({2-[(Benzyloxy)methyl]-2-(2,2-dimethoxyethyl)pent-4-yn-1-yl}oxy)methyl]benzene was prepared according to the modified literature procedure エラー! 参照元が見つかりません。 using 3-bromo-1-propyne instead of 1-bromo-2-butyne.

Colorless oil.

R_f = 0.45 (4:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 3292, 2928, 2905, 2862, 1454, 1365, 1099, 698.

^1H NMR (400 MHz, CDCl_3): δ 7.32-7.31 (m, 10H), 4.57 (t, 1H, J = 6.0 Hz), 4.50 (s, 4H), 3.45 (s, 4H), 3.26 (s, 6H), 2.39 (d, 2H, J = 2.4 Hz), 1.94 (t, 1H, J = 2.4 Hz), 1.80 (d, 2H, J = 6.0 Hz).

^{13}C NMR (100 MHz, CDCl_3): δ 138.6, 128.2, 127.4, 127.3, 102.1, 81.4, 70.3, 52.5, 40.4, 34.5, 22.9.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{24}\text{H}_{30}\text{O}_4\text{Na}$, 405.2042; found, 405.2023.

[({2-[(Benzyloxy)methyl]-2-(2,2-dimethoxyethyl)hexa-4,5-dien-1-yl}oxy)methyl]benzene



To a solution of [({2-[(benzyloxy)methyl]-2-(2,2-dimethoxyethyl)pent-4-yn-1-yl}oxy)methyl]benzene (2.50 g, 6.54 mmol) in anhydrous 1,4-dioxane (65 mL) were added paraformaldehyde

(393 mg, 13.1 mmol), CuBr (281 mg, 1.96 mmol) and diisopropylamine (1.8 mL, 13 mmol). The mixture was refluxed for 9 h with stirring, and then treated with saturated aqueous NaHCO₃. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (14:1)] to afford [(2-[(benzyloxy)methyl]-2-(2,2-dimethoxyethyl)hexa-4,5-dien-1-yl)oxy)methyl]benzene (930 mg, 37%) as a yellow oil.

R_f = 0.50 (4:1 hexane/EtOAc).


IR ν (neat, cm⁻¹): 2928, 2858, 1954, 1454, 1364, 1116, 1098, 1076, 698.

¹H NMR (400 MHz, CDCl₃): δ 7.32 (m, 10 H), 5.06 (tt, 1H, *J* = 7.6, 7.6 Hz), 4.61-4.55 (m, 3H), 4.49 (s, 4H), 3.38 (s, 4H), 3.26 (s, 6H), 2.17 (dt, 2H, *J* = 7.6, 2.4 Hz), 1.70 (d, 2H, 2.4 Hz).

¹³C NMR (100 MHz, CDCl₃): δ 209.9, 138.7, 128.2, 127.4, 127.3, 102.3, 85.5, 73.5, 73.1, 72.7, 52.5, 41.0, 34.9, 32.4.

HRMS (ESI, [M+Na]⁺): calcd for C₂₅H₃₂O₄Na, 419.2198 found, 419.2180.


5,5-Bis[(benzyloxy)methyl]-7,7-dimethoxy-2-phenylhept-2-en-1-yl acetate¹⁰



136.0, 130.8, 128.7, 128.2, 128.2, 128.1, 127.7, 127.5, 127.4, 127.3, 127.3, 127.0, 127.0, 126.1, 102.4, 102.2, 73.2, 73.1, 72.9, 72.7, 69.2, 61.1, 52.7, 52.4, 41.3, 40.9, 35.2, 35.2, 32.0, 31.8, 20.9, 20.9.

HRMS (ESI, $[M+Na]^+$): calcd for $C_{33}H_{40}O_6Na$, 555.2723; found, 555.2709.


5,5-Bis[(benzyloxy)methyl]-7-oxo-2-phenylhept-2-en-1-yl acetate (**13f'**)



13f' (102 mg, 74%, *E:Z* = 3.2:1) was prepared from 5,5-bis[(benzyloxy)methyl]-7,7-dimethoxy-2-phenylhept-2-en-1-yl acetate (150 mg, 0.282 mmol) through deprotection with acid.

PTLC: toluene – EtOAc (9:1) 2 times. Pale yellow oil.

(*E*)-**13f'**




R_f = 0.21 (9:1 toluene/EtOAc).

IR ν (neat, cm^{-1}): 2859, 1738, 1717, 1454, 1366, 1227, 1097, 1027, 738, 700.


1H NMR (400 MHz, $CDCl_3$): δ 9.62 (t, 1H, J = 2.8 Hz), 7.31-7.20 (m, 15H), 5.78 (t, 1H, J = 8.0 Hz), 4.72 (s, 2H), 4.41 (s, 4H), 3.40 (d, 2H, J = 8.8 Hz), 3.33 (d, 2H, J = 8.8 Hz), 2.31 (d, 2H, J = 2.8 Hz), 2.27 (d, 2H, J = 8.0 Hz), 1.98 (s, 3H).

^{13}C NMR (100 MHz, $CDCl_3$): δ 202.0, 170.6, 138.6, 138.1, 137.6, 128.6, 128.3, 127.5, 127.5, 127.4, 127.3, 126.0, 73.2, 72.7, 68.9, 47.5, 43.0, 32.1, 20.9.

HRMS (ESI, $[M+Na]^+$): calcd for $C_{31}H_{34}O_5Na$, 509.2304; found, 509.2292.



NOESY correlation of (*E*)-**13f'**

(Z)-13f


$R_f = 0.22$ (9:1 toluene/EtOAc).

IR ν (neat, cm^{-1}): 2859, 1737, 1717, 1496, 1454, 1366, 1237, 1098, 1027, 739, 698.



^1H NMR (400 MHz, CDCl_3): δ 9.81 (t, 1H, $J = 2.8$ Hz), 7.32-7.23 (m, 15H), 5.98 (t, 1H, $J = 8.0$ Hz), 5.00 (s, 2H), 4.47 (s, 4H), 3.49 (d, 2H, $J = 9.2$ Hz), 3.45 (d, 2H, $J = 9.2$ Hz), 2.53 (d, 2H, $J = 8.0$ Hz), 2.47 (d, 2H, $J = 2.8$ Hz), 1.94 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3): δ 201.8, 170.9, 140.5, 138.0, 137.0, 129.3, 128.3, 128.3, 127.6, 127.6, 127.3, 126.1, 73.4, 72.6, 60.8, 47.5, 43.3, 32.3, 20.8.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{31}\text{H}_{34}\text{O}_5\text{Na}$, 509.2304; found, 509.2292.



NOESY correlation of **(Z)-13f**

**3,3-Bis[(benzyloxy)methyl]hepta-5,6-dienal**

Deacetalization of [(2-[(benzyloxy)methyl]-2-(2,2-dimethoxyethyl)hexa-4,5-dien-1-yl)oxy]methyl]benzene (90.0 mg, 0.229 mmol) with 3 M HCl aq. and AcOH/THF/ H_2O gave 3,3-Bis[(benzyloxy)methyl]hepta-5,6-dienal (79.0 mg, quant.).

Column: toluene – EtOAc (14:1). Colorless oil.

$R_f = 0.58$ (9:1 toluene/EtOAc).


IR ν (neat, cm^{-1}): 3030, 2917, 2860, 1954, 1717, 1496, 1454, 1365, 1205, 1097, 850, 698.

^1H NMR (400 MHz, CDCl_3): δ 9.80 (t, 1H, $J = 2.8$ Hz), 7.33-7.24 (m, 10H), 5.00 (dddd, 1H, $J = 8.4, 8.4, 6.8, 6.8$ Hz), 4.62 (dd, 1H, $J = 6.8, 2.4$ Hz), 4.61 (dd, 1H, $J = 6.8, 2.4$ Hz), 4.48 (m, 4H), 3.47 (d, 2H, $J = 9.2$ Hz), 3.43 (d, 2H, $J = 9.2$ Hz), 2.43 (d, 2H, $J = 2.8$ Hz), 2.26 (dd, 1H, $J = 8.4,$


2.4 Hz), 2.25 (dd, 1H, $J = 8.4, 2.4$ Hz).

^{13}C NMR (100 MHz, CDCl_3): δ 210.1, 202.1, 138.2, 128.3, 127.6, 127.5, 84.7, 74.1, 73.3, 72.6, 47.3, 43.2, 32.8.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{23}\text{H}_{26}\text{O}_3\text{Na}$, 373.1780; found, 373.1765.



1-[(*tert*-Butyldimethylsilyl)oxy]dec-9-yn-5-one



A slurry of magnesium turnings (546 mg, 22.4 mmol) in THF (10 mL) was treated with a few crystals of iodine. A solution of {(5-bromopentyl)oxy}(*tert*-butyl)dimethylsilane¹¹ (4.0 g, 15.0 mmol) in THF (5 mL) was added dropwise to the magnesium slurry. The mixture was refluxed for 1 h with stirring before addition of Weinreb amide¹² (928 mg, 5.99 mmol) in THF (10 mL) at 0 °C. The mixture was stirred at room temperature for 9 h, and then treated with aqueous NH_4Cl . The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (30:1)] to afford 1-((*tert*-butyldimethylsilyl)oxy)dec-9-yn-5-one (1.42 g, 84%) as a colorless oil.

$R_f = 0.51$ (4:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 3308, 2954, 2929, 2858, 1716, 1472, 1463, 1361, 1256, 1101, 837, 776.

^1H NMR (400 MHz, CDCl_3): δ 3.61 (t, 2H, $J = 6.0$ Hz), 2.55 (t, 2H, $J = 7.2$ Hz), 2.44 (t, 2H, $J = 7.2$ Hz), 2.23 (dt, 2H, $J = 7.2, 2.8$ Hz), 1.95 (t, 1H, $J = 2.8$ Hz), 1.79 (tt, 2H, $J = 7.2, 7.2$ Hz), 1.67-1.60 (m, 2H), 1.54-1.47 (m, 2H), 0.89 (s, 9H), 0.04 (s, 6H).

^{13}C NMR (100 MHz, CDCl_3): δ 210.0, 83.4, 68.9, 62.6, 42.5, 40.8, 32.1, 25.8, 22.1, 20.2, 18.2, 17.6, -5.5.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{16}\text{H}_{30}\text{O}_2\text{SiNa}$, 305.1913; found, 305.1905.

1-{4-[(*tert*-Butyldimethylsilyl)oxy]butyl}-2-methylenecyclopentan-1-ol



SmI_2 was prepared according to the literature procedure¹³; Samarium powder (3.00 g, 20.0 mmol) was stirred under argon for 24 h before 75 mL of THF was added. To the slurry were added iodine (2.53 g, 9.98 mmol) dissolved in THF (25 mL), and then the resulting mixture was stirred at 60 °C for 18 h. To the SmI_2 solution was added HMPA (6.9 mL, 40 mmol), and a solution of 1-((*tert*-butyldimethylsilyl)oxy)dec-9-yn-5-one (939 mg, 3.33 mmol) and *tert*-butyl alcohol (0.95 mL, 9.98 mmol) in THF (30 mL) successively at 0 °C. The mixture was stirred at 0 °C for 1.5 h, and then treated with water. The aqueous layer was extracted with Et₂O twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (20:1)] to afford 1-{4-[(*tert*-butyldimethylsilyl)oxy]butyl}-2-methylenecyclopentanol (626 mg, 66%) as a yellow oil.

R_f = 0.40 (4:1 hexane/EtOAc).


IR ν (neat, cm⁻¹): 3406, 2954, 2929, 2858, 1472, 1255, 1101, 836, 773.

¹H NMR (400 MHz, CDCl₃): δ 5.04 (s, 1H), 4.96 (s, 1H), 3.63 (t, 2H, J = 6.0 Hz), 2.55-2.48 (m, 1H), 2.36-2.28 (m, 1H), 1.75 (m, 3H), 1.69-1.61 (m, 2H), 1.59-1.36 (m, 6H), 0.90 (s, 9H), 0.06 (s, 6H).

¹³C NMR (100 MHz, CDCl₃): δ 158.1, 105.8, 80.5, 63.1, 39.3, 39.2, 33.3, 31.7, 26.0, 21.5, 20.7, 18.3, -5.3.

HRMS (ESI, [M+Na]⁺): calcd for C₁₆H₃₂O₂SiNa, 307.2069; found, 307.2062.

1-{4-[(*tert*-Butyldimethylsilyl)oxy]butyl}-2-methylenecyclopentyl acetate



To the solution of 1-{4-[(*tert*-butyldimethylsilyl)oxy]butyl}-2-methylenecyclopentanol (86.8 mg, 0.306 mmol) in anhydrous THF (1.5 mL) was added *n*-BuLi (2.6 M in THF, 0.18 mL, 0.46 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 h before addition of Ac₂O (46 μ L, 0.489 mmol). The mixture was stirred at room temperature for 1 h, and then treated with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (24:1)] to afford 1-{4-[(*tert*-butyldimethylsilyl)oxy]butyl}-2-methylenecyclopentyl acetate (40.8 mg, 41%, 98% b.r.s.m.) as a colorless oil.

$R_f = 0.67$ (4:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 2954, 2930, 2858, 1740, 1366, 1250, 1102, 836, 775.

^1H NMR (400 MHz, CDCl_3): δ 4.98 (s, 2H), 3.56 (t, 2H, $J = 6.0$ Hz), 2.55-2.47 (m, 1H), 2.30-2.23 (m, 1H), 2.15 (dt, 1H, $J = 13.2, 7.6$ Hz), 1.96-1.65 (m, 6H), 1.58-1.21 (m, 6H), 0.84 (s, 9H), 0.04 (s, 6H).

^{13}C NMR (100 MHz, CDCl_3): δ 169.9, 153.2, 107.5, 89.0, 62.9, 37.7, 36.6, 33.0, 31.4, 25.9, 22.1, 22.0, 20.2, 18.3, -5.3.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{18}\text{H}_{34}\text{O}_3\text{SiNa}$, 349.2175; found, 349.2168.

1-(4-Hydroxybutyl)-2-methylenecyclopentyl acetate



To a solution of 1-{4-[(*tert*-butyldimethylsilyloxy)butyl]}-2-methylenecyclopentyl acetate (39.9 mg, 0.123 mmol) in anhydrous THF (1 mL) were added TBAF (1.0 M in THF, 0.25 mL, 0.245 mmol) and AcOH (21 μL , 0.368 mmol). The mixture was stirred at room temperature for 20 h, and then treated with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (4:1)] to afford 1-(4-hydroxybutyl)-2-methylenecyclopentyl acetate (21.6 mg, 83%) as a yellow oil. $R_f = 0.11$ (4:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 3422, 2947, 2872, 1733, 1659, 1434, 1368, 1251, 1181, 1020, 893.

^1H NMR (400 MHz, CDCl_3): δ 5.04 (m, 2H), 3.65 (t, 2H, $J = 6.4$ Hz), 2.60-2.52 (m, 1H), 2.36-2.28 (m, 1H), 2.19 (dt, 1H, $J = 13.2, 7.6$ Hz), 2.00-1.91 (m, 4H), 1.89-1.74 (m, 2H), 1.59-1.33 (m, 7H).

^{13}C NMR (100 MHz, CDCl_3): δ 170.0, 153.1, 107.6, 88.9, 62.7, 37.5, 36.7, 32.9, 31.4, 22.2, 21.9, 20.2.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{12}\text{H}_{20}\text{O}_3\text{Na}$, 235.1310; found, 235.1304.

2-Methylene-1-(4-oxobutyl)cyclopentyl acetate (13g)



Dess-Martin oxidation of 1-(4-hydroxybutyl)-2-methylenecyclopentyl acetate (130.1 mg, 0.612 mmol) gave **13g** (79.4 mg, 61%).

Column: hexane – EtOAc (14:1). Colorless oil.


R_f = 0.40 (4:1 hexane/EtOAc).

IR ν (neat, cm⁻¹): 2956, 1735, 1434, 1368, 1249, 1183, 1018, 894.


¹H NMR (400 MHz, CDCl₃): δ 9.77 (s, 1H), 5.05 (s, 1H), 5.05 (s, 1H), 2.61-2.53 (m, 1H), 2.46 (t, 2H, *J* = 7.2 Hz), 2.38-2.29 (m, 1H), 2.19 (dt, 1H, *J* = 13.2, 8.0 Hz), 2.01-1.55 (m, 10H).

¹³C NMR (100 MHz, CDCl₃): δ 202.1, 169.8, 152.8, 107.8, 88.5, 43.9, 37.1, 36.6, 31.3, 22.1, 21.9, 16.6.

HRMS (ESI, [M+Na]⁺): calcd for C₁₂H₁₈O₃Na, 233.1154; found, 233.1149.



2-[(*tert*-Butyldimethylsilyl)oxy]-1-{4-[(4-methoxybenzyl)oxy]butyl}cyclohex-2-en-1-ol¹⁴



To a stirred mixture of magnesium turnings (678 mg, 27.9 mmol) and iodine (1 crystal) in anhydrous THF (8.0 mL) under reflux, a solution of 1-[(4-bromobutoxy)methyl]-4-methoxybenzene¹⁵ (5.70 g, 20.9 mmol) in anhydrous THF (2.0 mL) was added. Then a catalytic amount of 1,2-dibromoethane was added, and the reaction mixture was stirred for 2 h under reflux. To a solution of Grignard reagent was added a solution of 2-[(*tert*-butyldimethylsilyl)oxy]cyclohex-2-en-1-one¹⁴ (3.16 g, 13.9 mmol) in anhydrous THF (10 mL) at 0 °C. The mixture was stirred for 9 h, and then treated with saturated aqueous NH₄Cl. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (20:1)] to afford 2-[(*tert*-butyldimethylsilyl)oxy]-1-{4-[(4-methoxybenzyl)oxy]butyl}cyclohex-2-en-1-ol (3.97 g, 68%) as a colorless oil.

R_f = 0.41 (4:1 hexane/EtOAc).

IR ν (neat, cm⁻¹): 3485, 2932, 2857, 1513, 1248, 1180, 1098, 838, 780.


¹H NMR (400 MHz, CDCl₃): δ 7.25 (d, 2H, *J* = 8.8 Hz), 6.86 (d, 2H, *J* = 8.8 Hz), 4.80 (dd, 1H, *J* = 4.8, 3.6 Hz), 4.42 (s, 2H), 3.79 (s, 3H), 3.43 (t, 2H, *J* = 6.8 Hz), 2.09-1.92 (m, 3H),

1.79-1.46 (m, 8H), 1.48-1.23 (m, 2H), 0.93 (s, 9H), 0.18 (s, 3H), 0.16 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3): δ 159.0, 152.3, 130.7, 129.1, 113.6, 103.8, 72.4, 72.3, 70.0, 55.1, 39.1, 34.1, 30.3, 25.7, 24.3, 20.6, 19.3, 18.1, -4.6.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{24}\text{H}_{40}\text{O}_4\text{SiNa}$, 443.2594; found, 443.2581.

2-[(*tert*-Butyldimethylsilyl)oxy]-2-{4-[(4-methoxybenzyl)oxy]butyl}cyclohexan-1-one¹⁴⁾



To a solution of silyl enol ether (3.97 g, 9.44 mmol) in anhydrous MeOH (20 mL) was added K_2CO_3 (261 mg, 1.89 mmol). The mixture was stirred for 1 h, and then diluted with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (25:1)] to afford 2-[(*tert*-butyldimethylsilyl)oxy]-2-{4-[(4-methoxybenzyl)oxy]butyl}cyclohexan-1-one (3.77 g, 95%) as a colorless oil.

R_f = 0.56 (4:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 2951, 2935, 2855, 1723, 1616, 1513, 1248, 1099, 836, 777.

^1H NMR (400 MHz, CDCl_3): δ 7.23 (d, 2H, J = 8.8 Hz), 6.85 (d, 2H, J = 8.8 Hz), 4.41 (s, 2H), 3.78 (s, 3H), 3.42 (ddd, 2H, J = 6.0, 6.0, 1.2 Hz), 2.48 (dt, 1H, J = 13.6, 4.8 Hz), 2.37-2.29 (m, 1H), 1.92-1.84 (m, 2H), 1.82-1.71 (m, 3H), 1.69-1.56 (m, 5H), 1.50-1.39 (m, 1H), 1.26-1.18 (m, 1H), 0.87 (s, 9H), 0.16 (s, 3H), 0.00 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3): δ 211.5, 159.0, 130.6, 129.1, 113.6, 81.8, 72.4, 69.8, 55.1, 40.8, 39.4, 37.8, 29.9, 27.3, 25.9, 22.4, 19.7, 18.5, -2.5, -3.0.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{24}\text{H}_{40}\text{O}_4\text{SiNa}$, 443.2594; found, 443.2579.

tert-Butyl{(1-[4-[(4-methoxybenzyl)oxy]butyl]-2-methylenecyclohexyl)oxy}dimethylsilane



To a solution of methyltriphenylphosphonium iodide (21.2 g, 52.3 mmol) in anhydrous THF (80 mL) was added *n*-BuLi (2.6 M in THF, 20 ml, 52 mmol) at 0 °C. The mixture was stirred for 1 h at same temperature, and then a solution of 2-[(*tert*-butyldimethylsilyl)oxy]-2-{4-[(4-methoxybenzyl)oxy]butyl}cyclohexan-1-one (3.67 g, 8.72 mmol) in anhydrous THF (10 mL) was added. The mixture was refluxed for 12 h with stirring, and then treated with saturated aqueous NH_4Cl . The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was

purified by silica gel chromatography [toluene – hexane (1:4)] to afford *tert*-butyl {(1-[4-{(4-methoxybenzyl)oxy}butyl]-2-methylenecyclohexyl)oxy}dimethylsilane (2.34 g, 64%) as a colorless oil.

$R_f = 0.71$ (4:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 2933, 2856, 1612, 1513, 1465, 835, 772.

^1H NMR (400 MHz, CDCl_3): δ 7.25 (d, 2H, $J = 8.0$ Hz), 6.86 (d, 2H, $J = 8.0$ Hz), 4.98 (s, 1H), 4.71 (s, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.42 (m, 2H), 2.28 (d, 1H, $J = 13.2$ Hz), 1.97 (t, 1H, $J = 13.2$ Hz), 1.86-1.26 (m, 11H), 1.23-1.15 (m, 1H), 0.91 (s, 9H), 0.08 (s, 6H).

^{13}C NMR (100 MHz, CDCl_3): 159.1, 152.4, 130.8, 129.2, 113.7, 107.4, 78.3, 72.5, 70.3, 55.2, 41.7, 37.9, 33.9, 30.1, 27.8, 26.1, 24.0, 19.8, 18.7, -1.6, -2.0.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{25}\text{H}_{42}\text{O}_3\text{SiNa}$, 441.2801; found, 441.2794.

1-{4-[(4-Methoxybenzyl)oxy]butyl}-2-methylenecyclohexan-1-ol



To a solution of *tert*-butyl{(1-[4-{(4-methoxybenzyl)oxy}butyl]-2-methylenecyclohexyl)oxy}dimethylsilane (1.20 g, 2.87 mmol) in anhydrous THF (15 mL) was added TBAF (1.0 M in THF, 28.6 mL, 28.6 mmol). The mixture was refluxed for 6 d with stirring, and then treated with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (4:1)] to afford 1-{4-[(4-methoxybenzyl)oxy]butyl}-2-methylenecyclohexan-1-ol (820 mg, 94%) as a colorless oil.

$R_f = 0.24$ (4:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 3457, 2934, 2857, 1642, 1613, 1586, 1515, 1247, 1097, 1034, 820.

^1H NMR (400 MHz, CDCl_3): δ 7.25 (d, 2H, $J = 8.0$ Hz), 6.86 (d, 2H, $J = 8.0$ Hz), 4.89 (s, 1H), 4.77 (s, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.44 (t, 2H, $J = 6.4$ Hz), 2.32 (d, 1H, $J = 13.2$ Hz), 2.02 (m, 1H), 1.81 (m, 1H), 1.74-1.69 (m, 3H), 1.62-1.26 (m, 9H).

^{13}C NMR (100 MHz, CDCl_3): δ 59.1, 153.4, 130.7, 129.2, 113.7, 106.2, 75.2, 72.5, 70.0, 55.2, 41.03, 36.8, 33.8, 30.0, 27.9, 23.8, 19.7.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{19}\text{H}_{28}\text{O}_3\text{Na}$, 327.1936; found, 327.1925.

1-{4-[(4-Methoxybenzyl)oxy]butyl}-2-methylenecyclohexyl acetate



To a solution of 1-{4-[(4-methoxybenzyl)oxy]butyl}-2-methylenecyclohexan-1-ol (761 mg, 2.50 mmol) in anhydrous THF (25 mL) was added *n*-BuLi (2.6 M in THF, 1.4 mL, 3.8 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 h before addition of Ac₂O (378 μL, 4.00 mmol). The mixture was stirred at room temperature for 1 h, and then treated with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (14:1)] to afford 1-{4-[(4-methoxybenzyl)oxy]butyl}-2-methylenecyclohexyl acetate (335 mg, 39%, 98% b.r.s.m.) as a colorless oil.

R_f = 0.39 (4:1 hexane/EtOAc).


IR ν (neat, cm⁻¹): 2935, 2860, 1734, 1513, 1367, 1239, 1102, 1035.

¹H NMR (400 MHz, CDCl₃): 7.25 (d, 2H, *J* = 8.4 Hz), 6.87 (d, 2H, *J* = 8.4 Hz), 4.90 (s, 1H), 4.88 (s, 1H), 3.80 (s, 3H), 3.43 (t, 2H, *J* = 6.4 Hz), 2.25-2.07 (m, 3H), 2.05-1.99 (m, 5H), 1.90-1.84 (m, 1H), 1.72-1.67 (m, 1H), 1.64-1.54 (m, 5H), 1.39-1.21 (m, 2H).

¹³C NMR (100 MHz, CDCl₃): 169.6, 159.1, 148.6, 130.7, 129.2, 113.7, 108.4, 85.0, 72.5, 69.9, 55.2, 37.2, 33.5, 33.2, 29.8, 28.0, 22.5, 22.1, 19.8.

HRMS (ESI, [M+Na]⁺): calcd for C₂₁H₃₀O₄Na, 369.2042; found, 369.2033.

1-(4-Hydroxybutyl)-2-methylenecyclohexyl acetate



To the solution of 1-{4-[(4-methoxybenzyl)oxy]butyl}-2-methylenecyclohexyl acetate (768 mg, 2.22 mmol) in DCM (10 mL) was added DDQ (755 mg, 3.33 mmol) and water (1.1 mL). The mixture was stirred at room temperature for 1 h, and then treated with saturated aqueous NaHCO₃. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with saturated aqueous Na₂S₂O₃ and brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (4:1)] to afford 1-(4-hydroxybutyl)-2-methylenecyclohexyl acetate (318 mg, 63%) as a pale yellow oil.

R_f = 0.24 (2:1 hexane/EtOAc).


IR ν (neat, cm⁻¹): 3428, 2936, 2864, 1735, 1368, 1256, 1239, 1026.

¹H NMR (400 MHz, CDCl₃): δ 4.91 (s, 1H), 4.89 (s, 1H), 3.64 (t, 2H, *J* = 6.4 Hz), 2.27-2.11 (m, 3H), 2.09-1.99 (m, 5H), 1.93-1.87 (m, 1H), 1.76-1.78 (m, 1H), 1.60-1.53 (m, 5H), 1.36-1.26 (m, 2H).

^{13}C NMR (100 MHz, CDCl_3): δ 169.8, 148.5, 108.5, 85.1, 62.7, 37.3, 33.5, 33.1, 32.7, 27.9, 22.5, 22.1, 19.3.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{13}\text{H}_{22}\text{O}_3\text{Na}$, 249.1467; found, 249.1461.

2-Methylene-1-(4-oxobutyl)cyclohexyl acetate (**13h**)



Dess-Martin oxidation of 1-(4-hydroxybutyl)-2-methylenecyclohexyl acetate (318 mg, 1.47 mmol) gave **13h** (284 mg, 86%).

Column: hexane – EtOAc (9:1). Colorless oil.


R_f = 0.58 (2:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 2937, 2863, 1734, 1368, 1256, 1238.


^1H NMR (400 MHz, CDCl_3): δ 9.76 (t, 1H, J = 1.6 Hz), 4.92 (s, 1H), 4.90 (s, 1H), 2.45 (m, 2H), 2.27-2.22 (m, 1H), 2.15-1.91 (m, 8H), 1.71 (m, 1H), 1.56 (m, 5H).

^{13}C NMR (100 MHz, CDCl_3): δ 202.1, 169.5, 148.0, 108.6, 84.7, 43.7, 37.0, 33.3, 32.6, 27.7, 22.4, 21.9, 15.7.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{13}\text{H}_{20}\text{O}_3\text{Na}$, 247.1310; found, 247.1305.



Ethyl 4-(*N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}(4-methylbenzene)sulfonamide)-2-chloro-but-2-enoate



To a solution of triethyl 2-chloro-2-phosphonoacetate (0.69 mL, 3.23 mmol) in anhydrous THF (10 mL) was added *n*-BuLi solution (2.6 M in THF, 1.24 mL, 3.23 mmol). The mixture was stirred for 20 min at room temperature before slow addition of a solution of

N-[2-(*tert*-butyldimethylsilyloxy)ethyl]-4-methyl-*N*-(2-oxoethyl)benzenesulfonamide (1.00 g, 2.69 mmol) in anhydrous THF (10 mL) at -78 °C. The mixture was stirred at -78 °C for 5 h, and then treated with saturated aqueous NH_4Cl . The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (8:1)] to afford ethyl 4-(*N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}(4-methylbenzene)sulfonamide)-2-chlorobut-2-enoate (1.28 g, quant.) as a pale yellow oil.

$R_f = 0.60$ (2:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 2955, 2929, 2857, 1733, 1716, 1348, 1231, 1162, 1091, 837, 779.

^1H NMR (400 MHz, CDCl_3): major isomer: δ 7.64 (d, 2H, $J = 8.4$ Hz), 7.27 (d, 2H, $J = 8.4$ Hz), 6.45 (t, 1H, $J = 5.6$ Hz), 4.32 (d, 2H, $J = 5.6$ Hz), 4.22 (q, 2H, 7.2 Hz), 3.72 (t, 2H, $J = 5.6$ Hz), 3.22 (t, 2H, $J = 5.6$ Hz), 2.39 (s, 3H), 1.29 (t, 3H, $J = 7.2$ Hz), 0.82 (s, 9H), 0.00 (s, 6H). minor isomer: δ 7.66 (d, 2H, $J = 8.4$ Hz), 7.27 (d, 2H, $J = 8.4$ Hz), 6.94 (t, 1H, $J = 5.6$ Hz), 4.22 (q, 2H, 7.2 Hz), 4.13 (d, 2H, $J = 5.6$ Hz), 3.72 (t, 2H, $J = 5.6$ Hz), 3.24 (t, 2H, $J = 5.6$ Hz), 2.39 (s, 3H), 1.27 (t, 3H, $J = 7.2$ Hz), 0.82 (s, 9H), 0.00 (s, 6H).

^{13}C NMR (100 MHz, CDCl_3): mixture: 162.2, 161.5, 143.6, 142.7, 138.1, 136.4, 129.8, 127.2, 127.1, 125.5, 122.8, 62.6, 62.4, 62.3, 51.2, 50.9, 49.1, 48.4, 25.8, 21.5, 18.2, 14.1, 14.0, -5.54 .

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{21}\text{H}_{34}\text{ClNO}_5\text{SSiNa}$, 498.1513; found, 498.1500.

***N*-{2-[(*tert*-Butyldimethylsilyl)oxy]ethyl}-3-chloro-4-hydroxy-*S*-(4-methylphenyl)but-2-ene-1-sulfonamide**



To a solution of ethyl 4-(*N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}(4-methylbenzene)sulfonamide)-2-chlorobut-2-enoate (1.28 g, 2.69 mmol) in anhydrous DCM (15 mL) was added DIBAL solution (1.0 M in toluene, 8.1 mL, 8.1 mmol) at -78 °C. The mixture was allowed to warm up to 0 °C and stirred for 2 h, and then treated with MeOH and aqueous Rochelle salt. The mixture was stirred for 1.5 h, and then aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by silica gel chromatography [hexane – EtOAc (6:1)] to afford *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-3-chloro-4-hydroxy-*S*-(4-methylphenyl)but-2-ene-1-sulfonamide (941 mg, 81%) as a colorless oil. $R_f = 0.39$ (2:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 3470, 2958, 2932, 2857, 1342, 1159, 1090, 836.


^1H NMR (400 MHz, CDCl_3): major isomer: δ 7.63 (d, 2H, $J = 8.4$ Hz), 7.26 (d, 2H, $J = 8.4$ Hz),

5.68 (t, 1H, $J = 7.6$ Hz), 4.24 (brs, 2H), 3.98 (d, 2H, $J = 7.6$ Hz), 3.70 (t, 2H, $J = 6.0$ Hz), 3.21 (t, 2H, $J = 6.0$ Hz), 2.63 (br s, 1H), 2.38 (s, 3H), 0.82 (s, 9H), 0.03 (s, 6H). minor isomer: δ 7.65 (d, 2H, $J = 8.4$ Hz), 7.26 (d, 2H, $J = 8.4$ Hz), 5.78 (t, 1H, $J = 6.4$ Hz), 4.08 (m, 2H), 4.00 (d, 2H, $J = 6.4$ Hz), 3.69 (t, 2H, $J = 4.0$ Hz), 3.20 (t, 2H, $J = 4.0$ Hz), 2.63 (br s, 1H), 2.38 (s, 3H), 0.82 (s, 9H), 0.03 (s, 6H).

^{13}C NMR (100 MHz, CDCl_3): mixture: 143.6, 143.4, 137.0, 136.9, 136.8, 135.6, 129.8, 129.7, 127.2, 127.1, 125.3, 122.4, 66.1, 63.0, 62.1, 61.8, 50.0, 49.9, 47.1, 46.6, 25.8, 25.8, 21.5, 18.2, 14.2, -5.49, -5.52.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{19}\text{H}_{32}\text{ClNO}_4\text{SSiNa}$, 456.1407; found, 456.1401.

2-Chloro-4-[*N*-(2-hydroxyethyl)(4-methylbenzene)sulfonamide]but-2-en-1-yl acetate



2-Chloro-4-[*N*-(2-hydroxyethyl)(4-methylbenzene)sulfonamide]but-2-en-1-yl acetate (89.3 mg, 78%) was prepared from *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-3-chloro-4-hydroxy-*S*-(4-methylphenyl)but-2-ene-1-sulfonamide (136 mg, 1.96 mmol) through acetylation with Ac_2O and desilylation with *p*-toluenesulfonic acid monohydrate.

Column: hexane – EtOAc (2:1). Colorless oil.

$R_f = 0.41$ (1:1 hexane/EtOAc).


IR ν (neat, cm^{-1}): 3530, 2954, 2928, 2860, 1744, 1339, 1227, 1160, 1090, 1035.

^1H NMR (400 MHz, CDCl_3): major isomer: δ 7.70 (d, 2H, $J = 8.4$ Hz), 7.33 (d, 2H, $J = 8.4$ Hz), 5.78 (t, 1H, $J = 7.2$ Hz), 4.71 (s, 2H), 4.07 (d, 2H, $J = 7.2$ Hz), 3.75 (br s, 2H), 3.28 (m, 2H), 2.44 (s, 3H), 2.21 (brs, 1H), 2.07 (s, 3H). minor isomer: δ 7.70 (d, 2H, $J = 8.4$ Hz), 7.33 (d, 2H, $J = 8.4$ Hz), 5.83 (t, 1H, $J = 6.8$ Hz), 4.60 (s, 2H), 4.04 (d, 2H, $J = 6.8$ Hz), 3.75 (br s, 2H), 3.25 (m, 2H), 2.44 (s, 3H), 2.21 (brs, 1H), 2.07 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3): mixture: δ : 170.6, 143.8, 136.4, 131.6, 131.3, 130.0, 128.6, 127.3, 127.1, 124.8, 66.3, 61.9, 61.5, 60.9, 50.7, 49.9, 47.0, 46.7, 21.5, 20.7.

HRMS (ESI, $[\text{M}+\text{Na}]^+$): calcd for $\text{C}_{15}\text{H}_{20}\text{ClNO}_5\text{SNa}$, 384.0648; found, 384.0638.

2-Chloro-4-[*N*-(2-oxoethyl)(4-methylbenzene)sulfonamide]but-2-en-1-yl acetate (**13I**)



Dess-Martin oxidation of *N*-{2-[(*tert*-butyldimethylsilyl)oxy]ethyl}-3-chloro-4-hydroxy-*S*-(4-methylphenyl)but-2-ene-1-sulfonamide (80.0 mg, 0.221 mmol) gave **13I** (63.5 mg, 79%).

Column: hexane – EtOAc (2:1). Yellow oil.

$R_f = 0.49$ (1:1 hexane/EtOAc).

IR ν (neat, cm^{-1}): 2977, 2932, 1743, 1601, 1342, 1227, 1160, 1091, 1035.

^1H NMR (400 MHz, CDCl_3): major isomer: δ 9.57 (s, 1H), 7.70 (d, 2H, $J = 8.4$ Hz), 7.34 (d, 2H, $J = 8.4$ Hz), 5.80 (t, 1H, $J = 7.6$ Hz), 4.61 (s, 2H), 4.02 (d, 2H, $J = 7.6$ Hz), 3.95 (s, 2H), 2.45 (s, 3H), 2.08 (s, 3H). minor isomer: δ 9.58 (s, 1H), 7.71 (d, 2H, $J = 8.4$ Hz), 7.35 (d, 2H, $J = 8.4$ Hz), 5.84 (t, 1H, $J = 6.8$ Hz), 4.61 (s, 2H), 4.01 (d, 2H, $J = 6.8$ Hz), 3.86 (s, 2H), 2.45 (s, 3H), 2.11 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3): mixture: δ 197.3, 170.4, 144.2, 135.5, 132.9, 130.0, 127.5, 127.4, 127.3, 123.0, 66.0, 61.6, 56.7, 56.2, 46.8, 46.3, 21.5, 20.6

LRMS (EI) m/z (relative intensity): 330 $[\text{M}-\text{CHO}]^+$ (67), 299 (6), 155 (36), 147 (100).



HRMS (EI, $[\text{M}-\text{CHO}]^+$): calcd for $\text{C}_{14}\text{H}_{17}\text{ClNO}_4\text{S}$, 330.0567; found, 330.0562.

References



- 1) H. Tsukamoto, T. Matsumoto and Y. Kondo, *Org. Lett.*, 2008, **10**, 1047.
- 2) (a) I. Ohtani, T. Kusumi, Y. Kashman and H. Kakisawa, *J. Am. Chem. Soc.*, 1991, **113**, 4092. (b) J. A. Dale, D. L. Dull and H. S. Mosher, *J. Org. Chem.*, 1969, **34**, 2543. (c) J. A. Dale and H. S. Mosher, *J. Am. Chem. Soc.*, 1973, **95**, 512.
- 3) H. Suemune, K. Maeda, K. Kato and K. Sakai, *J. Chem. Soc., Perkin Trans. 1.*, 1994, 3441.
- 4) J. Montgomery and M. Song, *Org. Lett.*, 2002, **23**, 4009.
- 5) J.-T. Hong, X. Wang, J.-H. Kim, K. Kim, H. Yun and H.-Y. Jang, *Adv. Synth. Catal.*, 2010, **352**, 2949.
- 6) L. A. Gandon, A. G. Russell, T. Güveli, A. E. Brodewolf, B. M. Kariuki, N. Spencer and J. S. Snaith, *J. Org. Chem.*, 2006, **71**, 5198.
- 7) A. E. Pasqua, M. Matheson, A. L. Sewell and R. Marquez, *Org. Process Res. Dev.*, 2011, **15**, 467.
- 8) Q. Liang and J. K. De Brabander, *Tetrahedron*, 2011, **67**, 5046.
- 9) T. Hayashi, K. Okamoto, Y. Otomaru, R. Shintani and K. Ueyama, *J. Am. Chem. Soc.*, 2005, **127**, 54.
- 10) S. Husinec, M. Jadranin, R. Markovic, M. Petkovic, V. Savic and N. Todorovic, *Tetrahedron Lett.*, 2010, **51**, 4066.
- 11) A. Fuerstner, J. Mlynarski and M. Albert, *J. Am. Chem. Soc.*, 2002, **124**, 10274.
- 12) P. García-Domínguez, I. Lepore, C. Erb, H. Gronemeyer, L. Altucci, R. Álvarez and A. R. de Lera, *Org. Biomol. Chem.*, 2011, **9**, 6979.
- 13) M. Szostak, M. Spain and D. J. Procter, *J. Org. Chem.*, 2012, **77**, 3049.
- 14) M. Gulias, J. R. Rodriguez, L. Castedo and J. L. Mascarenas, *Org. Lett.*, 2003, **5**, 1975.
- 15) Z. F. Shi, W. Y. Chai, P. An and X. P. Cao, *Org. Lett.*, 2009, **11**, 4394.



^1H and ^{13}C NMR spectra

11a





11d









(R)-MTPA ester of (3S,4S)-11d





(S)-MTPA ester of (3S,4S)-11d





11e









(R)-MTPA ester of (3S,4S)-11e





(S)-MTPA ester of (3S,4S)-11e





11f









(R)-MTPA ester of (1R,2R)-11f





(S)-MTPA ester of (1R,2R)-11f






11f










(R)-MTPA ester of (1R,2S)-11f






(S)-MTPA ester of (1R,2S)-11f





11g





p-nitrobenzoate of 11g





(5*R*, 6*R*)-6-Hydroxyspiro[4.4]nonan-1-one





11h





p-nitrobenzoate of 11h





(R)-Spiro[4.5]decane-1,6-dione





11i





11i







11j





11k















13a









13b







13c









13d













13e

















13f

















(E)-13f











(Z)-13f

























13g























13h









13i











13j







13k

